

Calcium signals critical for egress and gametogenesis in malaria parasites depend on a multipass membrane protein that interacts with PKG

BALESTRA, Aurélia, *et al.*

Abstract

Calcium signaling regulated by the cGMP-dependent protein kinase (PKG) controls key life cycle transitions in the malaria parasite. However, how calcium is mobilized from intracellular stores in the absence of canonical calcium channels in *Plasmodium* is unknown. Here, we identify a multipass membrane protein, ICM1, with homology to transporters and calcium channels that is tightly associated with PKG in both asexual blood stages and transmission stages. Phosphoproteomic analyses reveal multiple ICM1 phosphorylation events dependent on PKG activity. Stage-specific depletion of *Plasmodium berghei* ICM1 prevents gametogenesis due to a block in intracellular calcium mobilization, while conditional loss of *Plasmodium falciparum* ICM1 is detrimental for the parasite resulting in severely reduced calcium mobilization, defective egress, and lack of invasion. Our findings suggest that ICM1 is a key missing link in transducing PKG-dependent signals and provide previously unknown insights into atypical calcium homeostasis in malaria parasites essential for pathology and disease transmission.

Reference

BALESTRA, Aurélia, *et al.* Calcium signals critical for egress and gametogenesis in malaria parasites depend on a multipass membrane protein that interacts with PKG. *Science Advances*, 2021, vol. 7, no. 13, p. eabe5396

DOI : 10.1126/sciadv.abe5396

PMID : 33762339

Available at:

<http://archive-ouverte.unige.ch/unige:150847>

Disclaimer: layout of this document may differ from the published version.



UNIVERSITÉ
DE GENÈVE

MICROBIOLOGY

Ca²⁺ signals critical for egress and gametogenesis in malaria parasites depend on a multipass membrane protein that interacts with PKG

Aurélia C. Balestra^{1*}, Konstantinos Koussis^{2,*†}, Natacha Klages¹, Steven A. Howell³, Helen R. Flynn³, Marcus Bantscheff⁴, Carla Pasquarello⁵, Abigail J. Perrin², Lorenzo Brusini¹, Patrizia Arboit⁵, Olalla Sanz⁶, Laura Peces-Barba Castaño², Chrislaine Withers-Martinez², Alexandre Hainard⁵, Sonja Ghidelli-Disse⁴, Ambrosius P. Snijders³, David A. Baker⁷, Michael J. Blackman^{2,7†}, Mathieu Brochet^{1†}

Calcium signaling regulated by the cGMP-dependent protein kinase (PKG) controls key life cycle transitions in the malaria parasite. However, how calcium is mobilized from intracellular stores in the absence of canonical calcium channels in *Plasmodium* is unknown. Here, we identify a multipass membrane protein, ICM1, with homology to transporters and calcium channels that is tightly associated with PKG in both asexual blood stages and transmission stages. Phosphoproteomic analyses reveal multiple ICM1 phosphorylation events dependent on PKG activity. Stage-specific depletion of *Plasmodium berghei* ICM1 prevents gametogenesis due to a block in intracellular calcium mobilization, while conditional loss of *Plasmodium falciparum* ICM1 is detrimental for the parasite resulting in severely reduced calcium mobilization, defective egress, and lack of invasion. Our findings suggest that ICM1 is a key missing link in transducing PKG-dependent signals and provide previously unknown insights into atypical calcium homeostasis in malaria parasites essential for pathology and disease transmission.

INTRODUCTION

Malaria is an important cause of global morbidity and mortality, accounting for around 405,000 deaths in 2018 (1). The disease is caused by parasites of the genus *Plasmodium*, which have a remarkable life cycle with multiple cellular differentiation events in both humans and mosquitoes. To sense and respond to changes in these very different environments, malaria parasites use an intracellular communication system that relies on intracellular messengers and protein kinases. Two key signaling molecules in these pathways are 3',5'-guanosine monophosphate (cGMP) and calcium, both of which regulate pivotal processes in most eukaryotes (2, 3).

The sole sensor of cGMP in malaria parasites is the cGMP-dependent protein kinase (PKG), which plays vital roles in most stages of the parasite life cycle, including the asexual blood stages that cause all the manifestations of clinical malaria. These roles include control of cellular events required to trigger release of merozoites from red blood cells (RBCs) (4, 5) and hepatocytes (6), induction of gametogenesis and parasite transmission upon ingestion of gametocytes by a blood-feeding mosquito (7), and sustaining cellular motility necessary for parasite dissemination (8, 9). A major function of PKG in all these processes is the tightly regulated mobilization of calcium from intracellular stores within seconds of activation (8, 10).

In mammalian cells, one of the two PKG isoforms, cGKI (or PKG1), is a well-established regulator of calcium homeostasis. cGKI activation lowers intracellular free calcium upon stimulation by nitric oxide, favoring smooth muscle relaxation or decreasing platelet activation (11). cGKI-dependent phosphorylation is known to regulate levels of cytosolic calcium via distinct mechanisms, including either decreased calcium influx by L-type calcium channels (12) or sequestration of calcium within intracellular stores. Increased calcium sequestration can be mediated by the phosphorylation of (i) the inositol 1,4,5-trisphosphate (IP₃) receptor-associated cGMP-kinase substrate (IRAG), which reduces calcium release from intracellular stores by IP₃ receptors (13); or (ii) phospholipase-C β3, decreasing IP₃ generation and subsequent calcium mobilization (14); or (iii) phospholamban, which enhances calcium sequestration by the sarcoplasmic reticulum calcium/adenosine triphosphatase (ATPase) pump (15). *Plasmodium* parasites are highly divergent from their mammalian hosts (16), and no genes encoding clear homologs of IRAG, IP₃ receptors, phospholamban, or L-type calcium channels have been identified in their genomes (3).

In the absence from *Plasmodium* of such key signaling molecules, it remains unknown how calcium is mobilized from intracellular stores. We reasoned that the identification of PKG-interacting proteins in *Plasmodium* would provide valuable new insights into calcium homeostasis. Here, we identify a multipass membrane protein, termed important for calcium mobilization-1 (ICM1; Pf3D7_1231400) that interacts with and is phosphorylated by PKG in two different *Plasmodium* developmental stages and species. Through stage-specific knockdown and reverse genetic approaches, we show that ICM1 is essential for calcium mobilization in both the clinically relevant asexual blood stages and in gametocytes that mediate transmission to mosquitoes. Our findings highlight this putative transporter or channel as a crucial link between PKG function and calcium signaling.

¹Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland. ²Malaria Biochemistry Laboratory, The Francis Crick Institute, London NW1 1AT, UK. ³Mass Spectrometry Proteomics Platform, The Francis Crick Institute, London, UK. ⁴Cellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, 69117 Heidelberg, Germany. ⁵Proteomics Core Facility, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland. ⁶Diseases of the Developing World Global Health Pharma Unit, GlaxoSmithKline, 28760 Tres Cantos, Spain. ⁷Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.

*These authors contributed equally to this work.

†Corresponding author. Email: konstantinos.koussis@crick.ac.uk (K.K.); mike.blackman@crick.ac.uk (M.J.B.); mathieu.brochet@unige.ch (M.B.)

RESULTS

Plasmodium PKG interacts with ICM1, a multipass membrane protein, in both asexual and sexual stages

To identify potential PKG-interacting partners in *Plasmodium falciparum*, we used a previously established transgenic parasite line expressing PKG fused at its C terminus to a triple hemagglutinin (HA) tag (PfPKG-HA) (17). PfPKG-HA was immunoprecipitated from extracts of mature schizonts using anti-HA-conjugated magnetic beads and the eluates analyzed by quantitative tandem mass spectrometry (MS/MS). The most enriched protein coimmunoprecipitated with PfPKG-HA was identified with high confidence as Pf3D7_1231400, annotated as a putative amino acid transporter (www.plasmodb.org), but henceforth referred to as ICM1 (Fig. 1A and data S1). To corroborate these findings, we generated a second transgenic *P. falciparum* line expressing a green fluorescent protein (GFP)-tagged PKG (PKG-GFP) (fig. S1, A to E). Mass spectrometric analysis of pull-downs from extracts of these parasites using anti-GFP antibodies similarly identified PfICM1 as a top hit (fig. S1F and data S1).

To independently validate the putative interaction between ICM1 and PKG, we took an orthogonal chemical proteomics approach. A potent PKG inhibitor (18) (ML10) was used on a Kinobead matrix (19) to identify the repertoire of *P. falciparum* proteins targeted by this compound. Proteomic profiling showed that ML10 prevented the binding of just four parasite proteins to kinase inhibitors; these were PfPKG, two calcium-dependent protein kinases (CDPK1 and CDPK4), and PfICM1. The selectivity of ML10 for *Plasmodium* PKG exploits the presence of a small threonine gatekeeper residue in the enzyme adenosine triphosphate binding pocket (18). As both CDPK1 and CDPK4 also have small serine gatekeeper residues (20), it is likely that ML10 binds these two kinases directly. However, identification of a nonkinase hit in the Kinobead experiments likely reflects either off-target effects of the compound or capture of kinase-associated proteins. These results, combined with the pull-down data, fully support a direct interaction between PKG and ICM1 (Fig. 1B and data S1).

To interrogate whether the interaction between PKG and ICM1 is conserved across *Plasmodium* species and developmental stages,

we exploited a previously described transgenic *Plasmodium berghei* line expressing HA3-tagged PKG (PbPKG-HA3) (8) to immunoprecipitate PbPKG-HA3 from extracts of schizonts and gametocytes. Quantitative MS showed that in both stages, PbICM1 (PBANKA_1446100) was the most enriched protein coimmunoprecipitated with PbPKG-HA3 (Fig. 1, C and D, and data S1). To further validate these results in a reciprocal manner, we generated a PbICM1-HA3 line (fig. S1G). No signal was observed for PbICM1-HA3 in Western blot analysis of schizont or gametocyte extracts from this line, possibly due to low abundance of PbICM1. Consistent with this observation, no specific immunofluorescence signal could be observed in both schizonts and gametocytes. Nevertheless, immunoprecipitation (IP) of PbICM1-HA3 from extracts of both schizonts and gametocytes recovered multiple peptides, identified by MS to encompass up to 28% coverage of PbICM1. As expected, based on the PbPKG IPs, PbPKG was the most enriched protein coimmunoprecipitated with PbICM1-HA3 in both stages (Fig. 1, C and D, and data S1). Notably, no peptides from PbCDPK1 or PbCDPK4 were recovered from either immunoprecipitate, confirming that these kinases do not interact with PbPKG or PbICM1 as previously suggested (10).

To further characterize the specificity of PbPKG and PbICM1 co-IPs in gametocytes, we compared the relative abundance of proteins recovered in both immunoprecipitates with those of seven other proteins involved in gametogenesis (21). Nine-dimensional principal components analysis (PCA) of all detected proteins confirmed the clustering of PbPKG and PbICM1, consistent with the formation of a complex (Fig. 1D). Together, these results demonstrate a conserved interaction between ICM1 and PKG in at least two developmental stages of two different *Plasmodium* species.

Modeling of ICM1 shows resemblance to transporters and channels

ICM1 is a multipass membrane protein annotated as a putative amino acid transporter. A single ICM1 ortholog is present in all sequenced *Plasmodium* genomes, but no orthologs are evident in nonapicomplexan genomes. The N-terminal segment, which encompasses two conserved clusters of five and four transmembrane domains (TMDs),




Fig. 1. PKG interacts with ICM1 in *P. falciparum* and *P. berghei* schizonts and in *P. berghei* gametocytes. (A) Volcano plot depicting relative abundance of proteins identified by quantitative MS in pull-downs from *P. falciparum* PKG-HA compared to WT (control) parasites ($n = 3$). Significance (Student's t test) is expressed as \log_{10} of the P value (y axis). X axis, enrichment of interaction partners in the *P. falciparum* PKG-HA pull-down compared to controls. (B) Competitive chemoproteomic studies using Kinobeads on extracts of *P. falciparum* schizonts. (C) Mass spectrometric quantification of proteins immunoprecipitated from extracts of *P. berghei* PKG-HA3 ($n = 1$) and ICM1-HA3 ($n = 1$) schizonts. ND, not detected. (D) Mass spectrometric spectral count values for proteins copurifying with PbPKG-HA3 ($n = 2$) and PbICM1-HA3 ($n = 2$) gametocytes following IP and displayed in the first and second principal components compared with previously published IPs of CRK5, CDKs, SOC2, CDPK4, SOC1, SOC3, and MCM5.

respectively, shows high levels of identity between the *P. falciparum* and *P. berghei* orthologs, and these nine TMDs are also conserved in *Plasmodium yoelii*, *Plasmodium vivax*, *Plasmodium chabaudi*, and *Plasmodium knowlesi* (data S2). This region is separated from a predicted C-terminal TMD (TMD10) by ~1100 amino acid residues that are less conserved between all species. Homology modeling using Phyre2 (22) suggests weak similarity of the ICM1 N terminus to cation transporters, amino acid transporters, or IP₃ receptors (fig. S2A). To investigate this further, the Iterative Threading ASSEMBLY Refinement (I-TASSER) approach was used to model the N-terminal 1500 residues of *P. falciparum* ICM1. Following structure assembly simulation, the Protein Data Bank (PDB) was screened for proteins with the closest structural similarity to the model. The top PDB hit was an IP₃ receptor (rat cerebellum InsP₃R1, PDB: 6MU1) with a template modelling score of 0.967, a root mean square deviation of 2.06 Å, and a coverage of 98.7%, although amino acid identity between the two proteins was very low (8.4%) (fig. S2B). However, our analyses did not identify any domains similar to other calcium channels such as IP₃-binding domains or Ca²⁺ binding sites. Collectively, these findings suggest that ICM1 may represent a structurally divergent polytopic membrane protein with architectural similarities to mammalian channels, transporters, and IP₃ receptors.

ICM1 is phosphorylated in a PKG-dependent manner

The physical interaction between PKG and ICM1 raised the possibility of PKG regulating the function of ICM1 through phosphorylation. Several global phosphoproteome studies in *Plasmodium* have identified multiple phosphorylation sites between TMD9 and TMD10 in both *P. falciparum* ICM1 (23–25) and PbICM1 (8, 26). In a previous study, pharmacological inhibition of PKG activity in mature schizonts did not detect any differential ICM1 phosphorylation under the tested conditions (25). However, a phosphoproteome analysis of *P. berghei* guanylyl cyclase beta (GCB) mutant ookinetes, in which PKG activity is down-regulated (27), showed that PbICM1-S1288 was significantly less phosphorylated in this transgenic line (8). To shed more light on PKG-dependent phosphorylation of ICM1, we profiled the PKG-dependent phosphoproteomes in both gametocytes and schizonts. For the former, we examined phosphorylation events just 15 s after activation of gametocytes in the presence or absence of a selective PKG inhibitor (compound A) (10, 28), as PbPKG activity during gametogenesis is only required during the first 15 s following stimulation by xanthurenic acid (XA) (8, 10). Compound A was used at 1 μM, a concentration that did not impair exflagellation of a line expressing a resistant PKG^{T619Q}-HA allele indicating the selectivity of this small molecule under these experimental conditions (10). In the case of *P. falciparum* schizonts, we generated a conditional knockout (cKO) of PKG to investigate the phosphoproteome changes in PKG-null mutants. Treatment of this line, termed *pfpkg:cKO*, with rapamycin (RAP) results in disruption of the *pfpkg* gene, expression of mCherry, and complete arrest of parasite replication due to the requirement of PKG for merozoite egress (fig. S3 and movie S1) (5).

Given the low abundance of PbICM1 in gametocytes, we used SDS-polyacrylamide gel electrophoresis (PAGE) fractionation to enrich for proteins of molecular mass between 180 and 220 kDa. Analysis of these proteins identified 957 phosphopeptides mapping onto 610 proteins (data S3). Upon pharmacological inhibition of PbPKG, 410 phosphopeptides were less phosphorylated, a large response

amplitude that probably reflects the early requirement for PbPKG during gametogenesis (Fig. 2A). Conditional disruption of PfPKG had a similarly profound effect on the *P. falciparum* global schizont phosphoproteome, with more than 1000 phosphopeptides being significantly hypophosphorylated (Fig. 2B and data S4). Gene Ontology (GO) term enrichment analysis of hypophosphorylated proteins in *P. berghei* gametocytes suggested deregulation of both synthesis and mitosis cell cycle phases, which are initiated by calcium mobilization (Fig. 2C and data S3) (26, 29, 30). A similar analysis of the hypophosphorylated proteins in *P. falciparum* schizonts suggested potential defects in RNA processing and splicing (Fig. 2D and data S4).

The previously identified cGMP-dependent phosphorylation of enzymes involved in the metabolism of inositol phospholipids in *P. berghei* ookinetes (8, 10) was confirmed here for both schizonts and gametocytes. We then focused our attention on ICM1 phosphorylation. Twelve PfICM1 phosphorylation sites were mapped in *P. falciparum* schizonts (Fig. 2B). Ten sites were hypophosphorylated in the absence of PfPKG, suggesting a general defect in phosphorylation of PfICM1 although only two sites (S1289 and S1875) exhibited a fold change of more than 1.8. In gametocytes, intensities of the eight nonphosphorylated peptides mapped onto PbICM1 were not affected by compound A, indicating that PbICM1 abundance is not dependent on PbPKG activity. We identified two PbICM1 phosphosites, of which S1145 was significantly down-regulated upon PbPKG inhibition. Phosphorylation of PbICM1-S1145 was previously shown to be up-regulated within seconds of gametocyte activation by XA (26) and so possibly represents an important event in PbICM1 regulation. We additionally interrogated the phosphorylation status of immunoprecipitated PbICM1-HA3 in gametocytes 15 s after activation, in the presence or absence of 1 μM compound A (Fig. 2E). Treatment with compound A had no effect on the interaction between PbPKG and PbICM1-HA3 or on the obtained coverage of PbICM1-HA3. However, S1203 was the only residue detected as phosphorylated following gametocyte activation by XA, and no phosphorylation of PbICM1-HA3 was detected upon inhibition of PbPKG. This suggests that ICM1-S1203 is also phosphorylated early during gametogenesis in a PKG-dependent manner.

Collectively, our results indicate that the phosphorylation of at least five ICM1 residues depends on PKG activation. Four of the detected PKG-dependent phosphorylation sites are clustered in a region encompassing residues Pf1162 (Pb1145) to Pf1357 (Pb1288), suggesting that this represents an important region for regulation of ICM1 function (Fig. 2F).

Stage-specific knockdown of PbICM1 reveals a crucial role in early calcium mobilization required to initiate gametogenesis

To study the function and essentiality of PbICM1 during gametogenesis, we first attempted to disrupt the *pbicm1* gene. The gene was previously suggested to be resistant to disruption in a global gene KO study (31), although a transient nonclonal population of parasites lacking *icm1* had been observed in the days following transfection in an independent study (32). We were here however unable to obtain a clonal *icm1*-KO population despite four independent attempts using highly efficient PlasmogEM vectors (33, 34). We then tagged endogenous ICM1 with an auxin-inducible degron (AID) coupled to an HA epitope tag (fig. S4A) to allow degradation of the fusion protein in the presence of auxin in a strain expressing the Tir1 protein (35). Addition of auxin to PbICM1-AID/HA gametocytes




Fig. 2. ICM1 is phosphorylated in a PKG-dependent manner. (A) Volcano plot showing the extent of differentially phosphorylated peptides in *P. berghei* gametocytes 15 s after XA stimulation in presence or absence of compound A (CA) ($n = 3$). (B) Volcano plots showing differentially phosphorylated peptides in DMSO- and RAP-treated *pfpkg::cKO* schizonts ($n = 5$). Blue dots correspond to identified PfICM1 phosphosites and black dots to PfPKG phosphosites. (C and D) GO term enrichment analysis for down-regulated phosphopeptides in 15-s activated gametocytes upon inhibition of PbPKG by compound A and of PfPKG-null schizonts. For the latter, a cutoff of Welch difference of < -1 and > 1 with $P < 0.05$ and a localization probability of > 0.7 represent a significantly regulated peptide. Representative terms are shown (for a full list of GO term enrichment analysis in PfPKG-null schizonts, see data S4). (E) Relative abundance of proteins coprecipitated with PbICM1-HA3 in 15-s activated gametocytes in the presence or absence of compound A. Inset: Representative spectra indicating that phosphorylation of PbICM1-S1203 is only detected in absence of compound A. (F) Schematic of PbICM1 and PfICM1 indicating predicted TMDs and phosphosites detected in this and previous studies.

did not lead to any defect in male gametogenesis. However, we could detect no Western blot signal for PbICM1-AID/HA; thus, we were unable to confirm successful degradation of the protein upon auxin treatment (fig. S4B). We thus opted for a stage-specific knockdown of PbICM1 by placing the endogenous *pbicm1* gene under the control of the *pbama1* promoter, which is active in schizonts but virtually silent in gametocytes (36). A *P_{ama1}ICM1* clone was readily obtained and reverse transcription quantitative polymerase chain reaction (PCR) analysis confirmed a two-fold reduction in *pbicm1* expression in purified *P_{ama1}ICM1* gametocytes (Fig. 3A).

To determine the requirement for PbICM1 during gametogenesis, we then compared the effect of *pbicm1* down-regulation with PKG inhibition. Although *P_{ama1}ICM1* gametocytes were microscopically indistinguishable from their wild-type (WT) counterparts, they did not form active exflagellation centers upon treatment with XA, phenocopying PKG-specific inhibition by 1 μ M compound A (Fig. 3B). A similar result was observed when *pbicm1* was placed instead under the control of the *clag9* promoter, which similarly down-regulates *pbicm1* in gametocytes (fig. S4, C to E). In addition, PbICM1 down-regulation or PbPKG inhibition both led to significant




Fig. 3. Stage-specific knockdown of Pbc1CM1 partially phenocopies PKG inhibition. (A) Relative levels of *pbicm1* mRNA in WT and *P_{ama1}/ICM1* gametocytes. FC, fold change. (B) Knockdown of Pbc1CM1 impairs exflagellation. (C) *P_{ama1}/ICM1* male gametocytes show a strong reduction in fully assembled axonemes. Insets: Representative images. Scale bars, 2 μ m. (D) Proportion of male gametocytes undergoing DNA replication determined at 1 min postactivation (p.a.) and expressed as a percentage of polyploid (>1n) cells. Insets: Gating used for the analysis. (E) Egress from RBCs was quantified by flow cytometry based on the presence of the RBC membrane marker Ter-119 in gametocytes, 15 min p.a. Insets: IFA of WT and *P_{ama1}/ICM1* gametocytes activated 15 min p.a. Scale bars, 2 μ m. (F) Fluorescence response kinetics of gametocytes loaded with Fluo-4 AM upon stimulation with 100 μ M XA. AUC, area under each curve. (G) Relative calcium response to 100 μ M XA of WT and *P_{ama1}/ICM1* gametocytes upon treatment with compound 2. (H) Fluorescence response of gametocytes loaded with Fluo-4 AM upon stimulation with A23187. (I) Fluorescence response of gametocytes loaded with Fluo-4 AM upon stimulation with BIPPO. (J) cGMP levels in WT and *P_{ama1}/ICM1* gametocytes upon stimulation with BIPPO. Error bars, \pm SD; numbers of independent replicates are indicated for each experiment; two-tailed unpaired *t* test.

decreases in axoneme formation, egress from the host RBC, and DNA replication, indicating an early requirement for PbICM1 in male gametogenesis (Fig. 3, C to E).

We previously showed that PKG is critical for mobilization of calcium from intracellular stores within seconds of gametocyte stimulation by XA (8). Consistent with a functional link between PbPKG and PbICM1, a strongly attenuated calcium mobilization was consistently observed in *P_{ama1}*ICM1 and *P_{clag9}*ICM1 gametocytes (Fig. 3F and fig. S4F). The residual signal observed in *P_{ama1}*ICM1 gametocytes could possibly be due to incomplete silencing of *icm1* or due to PbICM1-independent pathways downstream of PbPKG also involved in calcium mobilization. The residual calcium mobilization observed in *P_{ama1}*ICM1 gametocytes was 10 times more sensitive to PKG inhibition by compound 2 compared with WT parasites, further strengthening the evidence for a functional interplay between PbPKG and PbICM1 (Fig. 3G). *P_{ama1}*ICM1 and *P_{clag9}*ICM1 gametocytes responded normally to the calcium ionophore A23187, indicating similar levels of mobilizable intracellular calcium in *P_{ama1}*ICM1 and WT gametocytes (Fig. 3H and fig. S4G).

To define the functional requirement for PbICM1 in the first seconds of gametogenesis, we took advantage of a phosphodiesterase (PDE) inhibitor, BIPPO, which elevates levels of cGMP in *Plasmodium* by preventing its degradation and leading to PKG activation (37). As expected, elevation of cGMP by BIPPO led to calcium release in WT gametocytes. In stark contrast, the calcium response to PDE inhibition was strongly reduced in the *P_{ama1}*ICM1 line (Fig. 3I and fig. S4H). However, chemical inhibition of PDEs and XA stimulation induced comparable cGMP levels in both WT and *P_{ama1}*ICM1 gametocytes, indicating that PbICM1 is not required to control cGMP homeostasis upstream of PKG (Fig. 3J). Together, these results indicate that PbICM1 is required for PKG-dependent mobilization of intracellular calcium.

Loss of PfICM1 in asexual blood stages inhibits calcium mobilization leading to inefficient egress and invasion

To study the function of PfICM1 and its link to PKG function in *P. falciparum* asexual blood stages, we investigated the phenotypic consequences of PfICM1 disruption. Because *pficm1* was predicted to be essential (38), we decided to disrupt the gene conditionally using the RAP-inducible DiCre system (39). Generation of the *pficm1:cKO* line was achieved in two steps using a marker-free Cas9-mediated strategy. In the first of these, we modified the 3' end of the gene by fusing it to a C-terminal HA3 epitope tag followed by a *loxN* site, a T2A peptide and an out-of-frame GFP sequence (fig. S5, A and B). The *pficm1:HA* parasites displayed normal replication rates, indicating that the modification had no impact on parasite fitness (fig. S5C). In a second gene manipulation step, we replaced intron 1 of *pficm1* in the *pficm1:HA* line with a *2loxPint* element (5), creating line *pficm1:cKO* (fig. S5D). DiCre-mediated recombination between the two *loxN* sites (one within the *2loxPint* and one downstream of the HA tag) was predicted to severely truncate the *pficm1* gene while simultaneously positioning the downstream GFP in frame, enabling its expression as a reporter of successful excision (fig. S5, E and F). Immunofluorescence (IFA) analysis of dimethyl sulfoxide (DMSO)- and RAP-treated schizonts of line *pficm1:cKO* alongside a WT control did show evidence of protein regulation but the very low levels of protein expression prevented us from localizing the protein (fig. S5G).

Monitoring of DMSO- and RAP-treated *pficm1:cKO* parasites under standard static culture conditions showed complete arrest of

growth in the RAP-treated cultures (Fig. 4A). RAP-treated parasites formed morphologically normal mature schizonts at the end of the erythrocytic cycle of treatment (cycle 0), indicating no effects on intracellular development. However, very few schizonts from the RAP-treated cultures underwent egress, resulting in a significant reduction in newly invaded rings (Fig. 4B). To seek further insights, we monitored the behavior of DMSO- and RAP-treated *pficm1:cKO* schizonts by time-lapse video microscopy. As shown in Fig 4C and movie S2, PfICM1-null schizonts exhibited an abnormal phenotype, with either complete loss of egress or rounding up with increased intracellular merozoite mobility (indicative of parasitophorous vacuole membrane rupture (40)) but no obvious rupture of the RBC membrane, with very few merozoites escaping the confines of the RBC. Quantification of the videos showed fewer egress events and a significant delay in time to egress for the PfICM1-null parasites (Fig. 4, D and E). No examples were observed of the explosive egress typical of WT parasites, although following prolonged incubation free PfICM1-null merozoites were visible (Fig. 4B and fig. S6A). To further characterize the phenotype, we compared egress of both DMSO- and RAP-treated *pfjpkc:cKO* and *pficm1:cKO* schizonts by monitoring the appearance in culture supernatants of the parasitophorous vacuole protein Serine Repeat Antigen 5 (SERA5). No release of SERA5 occurred in cultures of PfPKG-null parasites, while in marked contrast processed SERA5 appeared in the medium of PfICM1-null parasites, albeit with a delay compared to DMSO-treated parasites (fig. S6, B and C). Because proteolytic processing of SERA5 requires discharge of the protease SUB1 from exosomes (41), this result suggests that protein discharge from these secretory organelles is not affected by loss of ICM1. No differences in cellular cGMP levels were detectable in DMSO- and RAP-treated *pficm1:cKO* parasites (Fig. 4F). Collectively, these results suggested a role for PfICM1 in egress downstream of PKG activation.

Given the loss of long-term viability in static cultures of PfICM1-null parasites, we addressed whether the egress defect could be overcome by mechanical shear stress. As shown in Fig. 4G, even under shaking conditions, production of new rings was severely compromised in RAP-treated *pficm1:cKO* cultures. This prompted us to examine release of other secretory organelle proteins and in particular of AMA1, an essential invasion protein that translocates from micronemes to the surface of daughter merozoites at or just before the point of egress (42). As shown in Fig. 4H, comparative IFA revealed a severe defect in AMA1 discharge in the PfICM1-null schizonts. It was concluded that this likely explains the loss of invasion in the PfICM1-null parasites.

Release of micronemal contents has been linked to a calcium signaling pathway essential for egress and invasion, involving at least one calcium-dependent protein kinase, PfCDPK5 (43). To address the question of whether loss of ICM1 leads to a defect in calcium mobilization, we used the PDE inhibitor zaprinast to artificially activate PKG by prematurely increasing cGMP levels, forcing a PKG-dependent increase in cytosolic calcium levels (8). Addition of DMSO (vehicle control) to both WT and PfICM1-null parasites showed no increase in calcium levels (Fig. 4I). Calcium levels in PfICM1-null parasites exposed to zaprinast were significantly reduced compared to controls, similar to our findings with *P_{ama1}*ICM1 gametocytes. In contrast, treatment with the calcium ionophore A23187 had similar effects in both DMSO- and RAP-treated *pficm1:cKO* schizonts, suggesting that intracellular calcium levels are unaffected by loss of ICM1 (Fig. 4, J and K). Our results indicate that PfICM1 is involved in downstream transduction of calcium signals essential for egress and invasion in asexual blood stages.




Fig. 4. PflCM1 is essential for parasite viability, microneme discharge, efficient egress, and invasion. (A) Replication of DMSO- and RAP-treated *pficm1:cKO* parasites ($n = 3$). (B) Giemsa-stained blood films showing normal development of DMSO- and RAP-treated *pficm1:cKO* schizonts 46 hours after treatment. By 50 hours, most control parasites had successfully invaded while very few rings formed in RAP-treated cultures. (C) Stills from time-lapse differential interference contrast (DIC) video microscopy of DMSO/RAP-treated *pficm1:cKO* schizonts. (D) Egress quantification of DMSO- and RAP-treated *pficm1:cKO* schizonts. ($n = 4$). P value derived from paired t tests. (E) Quantification of time to egress for each schizont. P value, unpaired two-tailed t test (DMSO, 209 schizonts; RAP, 55 schizonts). Error bars, \pm SD. (F) cGMP levels in DMSO- and RAP-treated *pficm1:cKO* schizonts ($n = 2$). P value, paired t test. (G) Invasion assays of DMSO- and RAP-treated *pficm1:cKO* schizonts. P values, paired t test. (H) Left: Representative IFA images of *pficm1:cKO* parasites showing translocated AMA1 in DMSO-treated or micronemal AMA1 in RAP-treated merozoites. Right: Quantification of AMA1 relocation ($n = 3$). At least 150 schizonts were quantified in each. Values, means \pm SD. (I to K) Relative Fluo-4 AM fluorescence response of DMSO- and RAP-treated *pficm1:cKO* schizonts after treatment with DMSO, zaprinast, or A23187 ($n = 4$). For the AUC, DMSO values were normalized to 1. Values, means \pm SD. P values, two tailed t test.

PflCM1 and PflPKG-dependent phosphoproteomes suggest functional overlap in schizonts

Given the physical interaction between ICM1 and PKG in *P. falciparum* schizonts and their roles in calcium mobilization, we further explored the functional link between the two proteins by determining

the impact of ICM1 depletion on the global schizont phosphoproteome. We reasoned that if ICM1 acts downstream of PKG and if its function is regulated directly or indirectly by PKG-dependent phosphorylation, then an overlap would be expected between the two phosphoproteomes.

Using an approach similar to that previously used for PfPKG, we identified 106 phosphosites from 75 proteins that are significantly hypophosphorylated upon disruption of PfICM1 (Fig. 5A and data S4). Proteins involved in cyclic nucleotide-dependent signaling cascades were among this set, including adenylyl cyclase beta (AC β), GC α , and CDPK1. Motif analysis of the hypophosphorylated phosphopeptides showed a strict preference for lysine in position -3, resembling a minimal cAMP-dependent protein kinase (PKA)/PKG recognition motif (KxxpS/pT) (Fig. 5B). A similar substrate preference was also described in a recent study on the impact of CDPK5 depletion on the schizont phosphoproteome (44). GO term enrichment analysis of this set of 75 proteins showed deregulation of cyclic nucleotide biosynthesis, ATPase activity and RNA splicing (GO:0000375), as also observed in the PfPKG phosphoproteome (Fig. 5C and data S4). Comparison of the two phosphoproteome sets identified 73 phosphosites in 67 proteins that are regulated by

both PKG and ICM1 in schizonts (Fig. 5D and data S4). These include proteins involved in signaling as well as in egress and invasion, such as CDPK1, DGK1 (diacylglycerol kinase), AC β , RhopH3 (high molecular weight rhoptry protein 3), and AMA1 (apical membrane antigen 1). Collectively, these data strongly support a functional link between the essential roles of PKG and ICM1.

DISCUSSION

Many genetic and chemical genetic studies have shown a clear requirement for PKG in specific calcium signals or calcium-dependent pathways (7, 8, 10, 41, 43), but the molecular partners involved in calcium mobilization have remained elusive (3). Here, we have identified ICM1 as a tightly associated PKG partner protein that plays a key role in calcium signals in both schizonts and gametocytes. Our data suggest that ICM1 mainly acts downstream of PKG, because




Fig. 5. Impact of PfICM1 disruption on the schizont phosphoproteome. (A) Volcano plot showing distribution of phosphopeptide abundance in the presence or absence of PfICM1. Red circles correspond to significantly down-regulated peptides and blue circles to significantly up-regulated peptides. A cutoff of Welch difference of <-0.875 and >0.875 with $P < 0.05$ and a localization probability of >0.7 represent significantly regulated peptides. (B) Motif analysis of the significantly down-regulated phosphosites in PfICM1-null parasites. All detected phosphopeptides were used as the reference dataset, with amino acids below the position line indicating residues unfavored for this position. Position 0 corresponds to the phosphorylated residue. (C) GO enrichment analysis of biological process and molecular function for proteins significantly hypophosphorylated in PfICM1-null parasites. Enriched terms with $P < 0.01$ are shown. (D) Venn diagram showing the number of phosphoproteins and the corresponding phosphopeptides significantly deregulated by PfPKG and PfICM1.

ICM1 does not seem to be required for calcium homeostasis during intraerythrocytic development but only for PKG-mediated calcium signals leading to egress and activation of gametogenesis. This suggests a temporally restricted role in calcium homeostasis across the *Plasmodium* life cycle. Future experiments will be needed to determine the impact of ICM1 ablation on CDPK activation in both asexual and sexual stages. Two putative orthologs of *icm1* are predicted in *Toxoplasma gondii*, a related apicomplexan parasite, which also relies on PKG-dependent calcium signals upstream of CDPKs to control egress, motility, and invasion. Could ICM1 be the long-sought *Plasmodium* IP₃ receptor or could it act as a calcium channel? Our modeling data suggest that ICM1 resembles a channel but the low amino acid sequence similarity indicates that if it is a calcium channel, then it is highly divergent from other well-studied calcium channels. ICM1 could possibly represent an evolutionary alternative pathway functionally replacing the IP₃-R and the associated IRAG proteins that bridge PKG and calcium in human cells. Recombinant and/or heterologous expression and biophysical analysis will be needed to evaluate the function of ICM1 as a calcium channel and to investigate its regulation by IP₃, other secondary messengers or even by PKG-dependent phosphorylation.

Interactions between kinases and other proteins are a common signaling mechanism, with the A-kinase anchoring proteins that bind to PKA or the mitogen-activated protein kinase scaffolding proteins being some of the best studied examples (45, 46). In contrast, little is known about proteins interacting with PKG in eukaryotes as few partners have been identified (13, 47–49). In *Plasmodium*, the only previous data available for a PKG-interacting protein came from an in vitro study using the kinase domain of PKG (50), while a putative interaction between PKG and ICM1 was detected in a very recent elegant study profiling a potent inhibitor of PKG. However, conditional knockdown of ICM1 in that work resulted only in a minor growth defect, perhaps due to the different conditional system used (51), the TetR-DOZI aptamer system, which may require more than one cycle to achieve efficient down-regulation (52). The phenotype observed in our study could be a consequence of the high efficiency of gene disruption obtained with the DiCre system, combined with the fact that gene disruption is at the genomic rather than the transcriptional level.

Our identification of the PKG-ICM1 interaction creates new and exciting questions regarding calcium homeostasis in apicomplexan parasites and further strengthens the notion that calcium regulation in this phylum could be regulated by a class of divergent channels.

MATERIALS AND METHODS

Ethics statement

All animal experiments were conducted with the authorization numbers GE/82/15 and GE/41/17, according to the guidelines and regulations issued by the Swiss Federal Veterinary Office.

Reagents

WR99210 was from Jacobus Pharmaceuticals (New Jersey, USA). RAP was from Sigma-Aldrich and used at 20 nM. The PKG inhibitors compound 2 (4-[7-[(dimethylamino)methyl]-2-(4-fluorophenyl)imidazol[1,2-*α*]pyridine-3-yl]pyrimidin-2-amine) and compound A (1,4-cyclohexanediamine, *N*-[3-[2-[(3-fluoro-2-pyridinyl)amino]-5-pyrimidinyl]imidazo[1,2-*b*]pyridazin-6-yl], trans-) were stored as a 10 mM stock in DMSO at –20°C, while working dilution was 1 μM. The

calcium ionophore A23187 and zaprinast were both from Sigma-Aldrich and used at 10 and 100 μM, respectively.

P. falciparum culture, transfection, and synchronization

All *P. falciparum* lines were maintained at 37°C in human RBCs in RPMI 1640 containing AlbuMAX II (Thermo Fisher Scientific), and medium was supplemented with 2 mM L-glutamine. Parasite synchronization and transfections were performed as previously described (53). Clonal lines were obtained by serial limiting dilution in flat bottomed 96-well plates, and single plaques were selected and grown in the presence of 1 μM 5-fluorocytosine (provided as clinical grade Ancotyl) to select for Cas9 plasmid-free and marker-free parasites. For parasite genomic DNA (gDNA) extraction, the Qiagen DNeasy Blood and Tissue kit was used. Genotype analysis PCR was done using Phusion polymerase (New England Biolabs). For *P. falciparum* experiments, DiCre activity was induced by RAP treatment of early rings (2 to 3 hours after invasion) as previously described (54). Samples for excision PCRs were collected 24 hours after RAP treatment.

P. berghei maintenance, purification, and transfection

P. berghei maintenance, purification, and transfection were performed as previously described (21). *P. berghei* ANKA strain (36) derived clones 2.34 (27) and 615 (35), together with derived transgenic lines, were grown and maintained in CD1 outbred mice. Six- to 10-week-old mice were obtained from Charles River Laboratories, and females were used for all experiments. Mice were specific pathogen free (including *Mycoplasma pulmonis*) and subjected to regular pathogen monitoring by sentinel screening. They were housed in individually ventilated cages furnished with a cardboard mouse house and Nestlet, maintained at 21° ± 2°C under a 12-hour light/dark cycle, and given commercially prepared autoclaved dry rodent diet and water ad libitum. The parasitemia of infected animals was determined by microscopy of methanol-fixed Giemsa-stained thin blood smears.

For gametocyte production, parasites were grown in mice that had been phenyl hydrazine-treated 3 days before infection. One day after infection, sulfadiazine (20 mg/liter) was added in the drinking water to eliminate asexually replicating parasites. Microgametocyte exflagellation was measured 3 or 4 days after infection by adding 4 μl of blood from a superficial tail vein to 70 μl of exflagellation medium [RPMI 1640 containing 25 mM Hepes, 4 mM sodium bicarbonate, 5% fetal calf serum (FCS), and 100 μM XA (pH 7.4)]. To calculate the number of exflagellation centers per 100 microgametocytes, the percentage of RBCs infected with microgametocytes was assessed on Giemsa-stained smears. For gametocyte purification, parasites were harvested in suspended animation (SA) medium [RPMI 1640 containing 25 mM Hepes, 5% FCS, and 4 mM sodium bicarbonate (pH 7.20)] and separated from uninfected RBCs on a Histodenz (Sigma-Aldrich) cushion made from 48% of a Histodenz stock [27.6% (w/v) Histodenz in 5.0 mM tris-HCl, 3.0 mM KCl, and 0.3 mM EDTA (pH 7.20)] and 52% SA (final pH 7.2). Gametocytes were harvested from the interface. To induce ICM1-AID/HA degradation, 1 mM auxin dissolved in ethanol was added to purified gametocytes for 1 hour.

Schizonts for transfection were purified from overnight in vitro culture on a Histodenz cushion made from 55% of the Histodenz stock and 45% phosphate-buffered saline (PBS). Parasites were harvested from the interface and collected by centrifugation at 500g for 3 min, resuspended in 25 μl of Amaxa Basic Parasite Nucleofector solution (Lonza), and added to 10 to 20 μg of DNA dissolved in 10 μl of H₂O. Cells were electroporated using the FI-115 program of

the Amaxa Nucleofector 4D. Transfected parasites were resuspended in 200 μ l of fresh RBCs and injected intraperitoneally into mice. Parasite selection with pyrimethamine (0.07 mg/ml; Sigma-Aldrich) in the drinking water (pH \sim 4.5) was initiated 1 day after infection.

Plasmid construction and genotyping of *P. falciparum* transgenic lines

Oligonucleotides used in this study are shown in table S1. To create line PKG-GFP, the triple HA tag from plasmid pHH1-PfPKG-HA (17) was replaced by enhanced GFP (eGFP). Briefly, eGFP was PCR-amplified from plasmid pBAT-SIL6 (55) using primers GFP_For and GFP_Rev. The PCR product was digested with Avr II and Xho I and ligated to vector pHH1-PfPKG-HA previously digested with the same enzymes. Plasmid was transfected into 3D7 *P. falciparum*, and growth medium was replaced 24 hours after transfection with fresh medium containing 2.5 nM WR99210. Parasites were subjected to culture in the absence of WR99210 (3 cycles) followed by culturing with drug to select for transgenic parasites. Clonal lines were confirmed by PCR using primers wtpkg_For and 3utr_Rev and maintained in the presence of WR99210.

The DiCre-expressing B11 line (39) was used to generate line *icm:cKO* in two steps. The first step aimed at modifying the 3' end of the gene. To achieve that, a commercially obtained construct (GeneArt, Thermo Fisher Scientific) contained in tandem: (i) a 5' homology arm of 456-base pair (bp) endogenous and 255 bp of synthetic sequence comprising the 3' end of exon 2 and the whole of exon 3; (ii) a fragment comprising a triple HA tag, *loxN*, and the 3' 46 bp of the *sera2* intron; and lastly, (iii) the first 408 bp of *pficm1* 3' untranslated region (3'UTR) as a 3' homology arm. This plasmid (pMX_*icm1-int*) was digested with Sal I/Sac I and a T2A peptide followed by a GFP gene (fragment obtained from plasmid pT2A_D1_cKO, a gift from E. Deu) was cloned in after the 3' end of the *sera2* intron, resulting in plasmid pMX_*icm1_2*. A single guide RNA (sgRNA) targeting sequence TTGATTAAATAAATATATAA was inserted into a previously described pDC2 plasmid expressing Cas9, resulting in plasmid pDC2-*icm1_2g*. The repair plasmid (pMX_*icm1_2*) was linearized overnight with Bgl II and transfected in B11 parasites together with plasmid pDC2_*icm1_2g*. Integration was confirmed by PCR, using primer pairs L2_For/L2_Rev and L2_For/L2_HA. This clonal line (*icm1:HA*) was obtained via limiting dilution and was used for the second modification step, which involved replacing the endogenous intron 1 with the 2loxPint module (5). A commercially obtained construct (GeneArt, Thermo Fisher Scientific) was used (pMX_*icm1_2loxPint*), containing the 2loxPint module flanked by approximately 400 bp of endogenous sequence as homology arms. This vector was linearized with Bgl II and cotransfected with a pDC2-based Cas9 plasmid (56), harboring the sgRNA targeting sequence ATTTCAAAGGACTTACTTTA, in line *icm1_HA*. Clonal lines were obtained as described above, and integration was confirmed using primer pairs L1_For/L1_Rev.

To create a conditional KO of PfPKG, vector pDC_loxnPKG:lox22mCherry was digested with Xba I and Nhe I. The latter restriction site was blunted and the vector was religated resulting in vector pDC_lox22mCherry. This plasmid was linearized overnight with Sca I and transfected together with the pDC2-pkg Cas9 plasmid into *P. falciparum* line *pfpkg_2lox* (5). Correct 5' and 3' integration were verified by PCR using primers wtpkg_For/5int_Rev. The absence of the endogenous locus was confirmed using primers exon1_For/PKGutr_Rev.

Plasmid construction and genotyping of *P. berghei* transgenic lines

The oligonucleotides used to generate and genotype the mutant parasite lines are in table S1.

Restriction/ligation cloning

To generate the P_{ama1}ICM1 line, the plasmid pOB116-ama1 was used (36). The first 1000 bp from *PbICM1* gene was amplified from gDNA using the primers 453 and 458. The PCR product was digested with Xho I and Not I and ligated into the pOB116-ama1 plasmid previously digested with the same enzymes, resulting in the plasmid pAB025. The last 750 bp of *PbICM1* 5'UTR were amplified using primers 459 and 464, and the resulting fragment was digested with Hind III and Pst I and ligated into pAB026 previously digested with the same enzymes. The same strategy was used to generate the line P_{clag9}ICM1, with the plasmid pOB116-clag9 resulting in plasmid pAB027. Both plasmids were digested with the enzymes Eco RV and Hind III to be transfected in *P. berghei*.

Recombineering

ICM1-HA3 and ICM1-AID/HA tagging constructs were generated using phage recombineering in *Escherichia coli* TSA strain with PlasmogEM vectors (<http://plasmogem.sanger.ac.uk/>) as previously described (33, 34). The modified library inserts were then released from the plasmid backbone using Not I. The ICM1-AID/HA (PbGEM-645751) targeting vector was transfected into the 615 line (35). The ICM1-HA3 (PbGEM-121338) and ICM1-KO (PbGEM-265644) vectors were transfected into the 2.34 line.

Each mutant parasite was genotyped by PCR using three combinations of primers, specific for either the WT or the modified locus on both sides of the targeted region (experimental designs are shown in figs. S1 and S4). Controls using WT DNA were included in each genotyping experiment; parasite lines were cloned when indicated.

P. falciparum growth assays

Growth rates in *P. falciparum* mutant lines were performed as follows: synchronous ring-stage parasites at 0.1% parasitemia and 2% hematocrit were dispensed in triplicate into 12-well plates. Samples (50 μ l) from each well were collected at 0, 2, 4, and 6 days, stained with SYBR green, and analyzed by flow cytometry on a BD FACSVerser using BD FACSuite software. Data acquired were analyzed using FlowJo software.

P. falciparum egress and invasion assays

Mature schizonts were isolated by Percoll centrifugation and incubated for a further 3 hours in complete medium containing the reversible PKG inhibitor compound 2 (1 μ M). After removal of the inhibitor, schizonts were immediately resuspended in fresh serum-free RPMI 1640 at 37°C to allow egress. Schizont pellets and culture supernatants at $t = 0$ were collected as a control sample, while culture supernatants were collected by centrifugation at the relevant time points.

For invasion assays, mature schizonts were incubated at 2 to 4% parasitemia in 2% hematocrit under static or shaking conditions for 4 hours. Unruptured schizonts were removed by Percoll gradient, parasitemia was measured again, and the fold increase was calculated.

Calcium measurements

P. falciparum schizonts

Changes in calcium levels were measured using Fluo-4 acetoxymethyl ester (AM)-loaded (Thermo Fisher Scientific) parasites, and differences in fluorescence were measured over time on a BD FACSVerser

flow cytometer using BD FACSuite software. Briefly, schizonts were washed twice in phenol red– and serum-free RPMI medium (11835030, Thermo Fisher Scientific). Fluo-4 AM (5 μ M) was added to 1 ml of parasite preparation. Cells were incubated with Fluo-4 AM at 37°C for 45 min and washed twice in phenol red– and serum-free RPMI as above. Parasites were incubated for 30 min for deesterification followed by a further two washes. Schizonts were resuspended in 1 ml of warm phenol red– and serum-free RPMI. For Fluo-4 AM detection a 488-nm Blue Laser was used with a 530/30 filter. Fluorescence levels were measured for a period of 90 s to obtain a baseline read. Compounds were then added onto the cells, and reads were recorded for a further 3 min. Data analysis was done with FlowJo software.

***P. berghei* gametocytes**

To measure changes in the calcium level, *P. berghei* gametocytes were harvested in coelenterazine loading buffer (29) [CLB; PBS containing 20 mM Hepes, 20 mM glucose, 4 mM NaHCO₃, 1 mM EDTA, and 0.1% bovine serum albumin (BSA) (pH 7.2)]. Gametocytes were purified as described above and resuspended in 1 ml of CLB and loaded with 5 μ M of Fluo-4 AM for an hour. The parasites were then washed twice with CLB and resuspended in 500 μ l, and 20 μ l was added per well in a 96-well plate. Compound dispense and simultaneous fluorescence reading were performed by a FDSS/ μ CELL (Hamamatsu Photonics) for a period of 5 min. The fluorescence value of each time point was first normalized to the initial fluorescence value at 0 s ($F_t = n/F_t = 0$) and then by the vehicle control ($F_t = n/F_{vehicle} t = n/F_{vehicle} t = 0$).

Flow cytometry analysis of gametocytes

To analyze their DNA content, gametocytes were harvested in SA and purified as described above. Gametocytes were resuspended in 100 μ l and activated with 100 μ l of modified exflagellation medium [RPMI 1640 containing 25 mM Hepes, 4 mM sodium bicarbonate, 5% FCS, and 200 μ M XA (pH 8.0)]. Gametogenesis was stopped by ice-cold PBS containing Vybrant dye cycle violet (Life Technologies), and cells were stained for 30 min at 4°C. DNA content was determined using a Beckman Coulter Gallios 4 and analyzed with the Kaluza software. Per sample, >10,000 cells were analyzed.

Immunoblotting and immunofluorescence assays

P. falciparum

Synchronized *P. falciparum* schizonts were isolated by Percoll gradient centrifugation and washed in RPMI 1640 without Albumax. Parasites were extracted into a Triton X-100 buffer [20 mM tris-HCl (pH 7.4), 150 mM NaCl, 0.5 mM EDTA, and 1% Triton X-100, supplemented with 1 \times protease inhibitors, Roche]. Extracts were incubated on ice for 30 min then clarified by centrifugation at 12,000g for 15 min at 4°C. Supernatants were mixed with SDS sample buffer containing dithiothreitol (DTT) and incubated for 5 min at 95°C before fractionation by SDS-PAGE analysis on 4 to 15% Mini-PROTEAN TGX Stain-Free Protein Gels (Bio-Rad). Transfer to nitrocellulose membranes and probing for Western blot analysis were as described previously. A rabbit polyclonal human-PKG antibody (Enzo Life Sciences) was used for PKG detection at 1:1000. A GFP-specific monoclonal antibody 11814460001 (Roche) was used at 1:1000, as was a polyclonal rabbit anti-mCherry (ab167453; Abcam). A polyclonal rabbit anti-SERA5 antibody was used at 1:2000, and an anti-HSP70 antibody (a gift from E. Knuepfer, Francis Crick Institute) was used at 1:2000.

For IFA analysis, thin blood smears of wt, *pficm1:cKO* DMSO-, and RAP-treated Percoll-enriched schizonts were fixed in 4% (w/v) paraformaldehyde and permeabilized in 0.1% (v/v) Triton X-100. After blocking with 3% BSA, smears were probed with a rat anti-HA (3F10; 1:100) and a rabbit anti-SERA5 (1:500). For AMA1 relocation, vehicle (DMSO) or RAP-treated Percoll-enriched *pficm1:cKO* schizonts were probed with a rabbit anti-AMA1 (1:200). Subsequently, slides were probed with the required Alexa Fluor 594–conjugated secondary antibody diluted (1:1000). Images were collected using a Nikon Eclipse Ni-E wide-field microscope with a Hamamatsu C11440 digital camera and 100 \times /1.45 numerical aperture (NA) oil immersion objective. Identical exposure conditions were used at each wavelength for each pair of mock- and RAP-treated samples under comparison. Images were processed using Fiji software (57).

P. berghei

Gametocyte immunofluorescence assays were performed as previously described (58). For HA and α -tubulin staining, purified cells were fixed with 4% paraformaldehyde and 0.05% glutaraldehyde in PBS for 1 hour, permeabilized with 0.1% Triton X-100/PBS for 10 min, and blocked with 2% BSA/PBS for 2 hours. Primary antibodies were diluted in blocking solution (rat anti-HA clone, 3F10, 1:1000; mouse anti- α -tubulin clone, DM1A, 1:1000; both from Sigma-Aldrich). Anti-rat Alexa 594, anti-mouse Alexa 488, anti-rabbit Alexa 488, and anti-rabbit Alexa 594 were used as secondary antibodies together with DAPI (4',6-diamidino-2-phenylindole) (all from Life Technologies), all diluted at 1:1000 in blocking solution. Confocal images were acquired with a LSM700 or a LSM800 scanning confocal microscope (Zeiss).

Time-lapse and live fluorescence microscopy

Viewing chambers were constructed as previously described (41). Images were recorded on a Nikon Eclipse Ni light microscope fitted with a Hamamatsu C11440 digital camera and Nikon N Plan Apo λ 63 \times /1.45 NA oil immersion objective. For time-lapse video microscopy, vehicle (DMSO) or RAP-treated schizonts were synchronized by incubation with the reversible PKG inhibitor compound 2 and then washed, mixed in equal proportions, and monitored for egress. Differential interference contrast (DIC) images were taken at 10-s intervals over 45 min, while fluorescence (GFP or mCherry) images were taken every 5 to 10 min to prevent bleaching. Time-lapse videos were analyzed and annotated using Fiji (57).

Measurement of intracellular cyclic nucleotide levels

Relative intracellular cGMP levels in mature schizonts were measured using the Direct cGMP ELISA kit (Enzo). RAP- or DMSO-treated *icm1:cKO* schizonts were Percoll-purified and lysed in the presence of 0.1 ml of 0.1 M HCl to harvest cGMP. Samples were incubated at room temperature for 5 min with intermittent vortexing. Standards were fitted to a sigmoidal curve and used to determine cyclic nucleotide concentrations in parasite samples.

ICM1 protein structure prediction

The homology models of PfICM1 were constructed initially using the Phyre2 Server in intensive mode (22). The I-TASSER meta-threading procedure (<https://zhanglab.ccmb.med.umich.edu/I-TASSER/>) was run to generate a molecular model of PfICM1, using the first 1500 amino acids of the protein (I-TASSER maximum allowed residues) and covering domains of the protein predicted to be highly helical (59–61). The local Meta-Threader Server identified

PDB 6MU1, 6JXC, 6RLB, and 6C08 as the top four threading templates for protein structure prediction, three of them being transporter proteins.

IP and MS analysis in *P. falciparum*

For pull-down analysis, frozen schizont preparations from lines PfPKG-HA, PKG-GFP, and 3D7 were resuspended in 100 μ l of lysis buffer [20 mM tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100, complete protease inhibitors and PhosSTOP] and extracted at 4°C for 30 min with intermittent vortexing. Extracts were clarified by centrifugation at 16,000g for 20 min at 4°C, filtered through 0.22 Corning Costar Spin-X centrifuge tube filters, and then incubated with 25 μ l of anti-HA magnetic beads (Pierce) or with 25 μ l of GFP-Trap Magnetic Agarose (ChromoTek) overnight at 4°C. Sample processing followed the manufacturer's protocol. Protein complexes were eluted from beads with the addition of 2 \times volumes of reduced 2 \times SDS sample buffer. Samples were incubated at 95°C for 5 min and run on 12% SDS-PAGE gels. Band slices covering the whole separation profile were excised and washed. Reduced and alkylated proteins were in-gel digested with 100 ng of trypsin (modified sequencing grade, Promega) overnight at 37°C. Supernatants were dried in a vacuum centrifuge and resuspended in 0.1% trifluoroacetic acid (TFA). Digested protein (1 to 10 μ l) acidified to a final concentration of 0.1% TFA was loaded on an UltiMate 3000 nanoRSLC HPLC (Thermo Fisher Scientific) at 15 μ l/min of 0.1% TFA onto a 2 mm by 0.3 mm Acclaim PepMap C18 trap column (Thermo Fisher Scientific) before the trap being switched to elute at 0.25 μ l/min through a 50 cm by 75 μ m EASY-Spray C18 column. A 90' gradient of 9 to 25% B over 37' and then 25 to 40% B over 18' was used followed by a short gradient to 100% B and back down to 9% B and a 20' equilibration in 9% B [A = 2% acetonitrile (ACN), 0.1% formic acid (FA); B = 80% ACN, 0.1% FA].

The Orbitrap was operated in "Data Dependent Acquisition" mode with a survey scan at a resolution of 120,000 from mass/charge ratio (m/z) of 300 to 1500, followed by MS/MS in "TopS" mode. Dynamic exclusion was used with a time window of 20 s. The Orbitrap charge capacity was set to a maximum of 1×10^6 ions in 10 ms, while the LTQ was set to 1×10^4 ions in 100 ms. Raw files were processed using MaxQuant 1.3.0.5 and Perseus 1.4.0.11 against a recent version of PlasmoDB (www.plasmodb.org). A decoy database of reversed sequences was used to filter false positives, at a peptide false detection rate of 1%.

IP and MS analysis in *P. berghei*

Sample preparation

Co-IPs of proteins were performed with purified gametocytes. The following IPs were performed: ICM1-HA3 in schizonts or gametocytes (15 s post activation +/- compound A) and PKG-HA3 in schizonts or gametocytes (15 s post activation +/- compound A). IPs from WT nonactivated gametocytes lacking an epitope tag were used as controls.

Samples were fixed for 10 min with 1% formaldehyde. Parasites were lysed in RIPA buffer [50 mM tris-HCl (pH 8), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS], and the supernatant was subjected to affinity purification with anti-HA antibody (Sigma-Aldrich) conjugated to magnetic beads. Beads were resuspended in 100 μ l of 6 M urea in 50 mM ammonium bicarbonate (AB). Two microliters of 50 mM dithioerythritol (DTE) were added, and the reduction was carried out at 37°C for 1 hour. Alkylation was performed by adding 2 μ l of 400 mM iodoacetamide for 1 hour

at room temperature in the dark. Urea was reduced to 1 M by addition of 500 μ l of AB, and overnight digestion was performed at 37°C with 5 μ l of freshly prepared trypsin (0.2 μ g/ μ l; Promega) in AB. Supernatants were collected and completely dried under speed vacuum. Samples were then desalted with a C18 microspin column (Harvard Apparatus) according to the manufacturer's instructions, completely dried under speed vacuum, and stored at -20°C.

Liquid chromatography electrospray ionization tandem mass spectrometry

Samples were diluted in 20 μ l of loading buffer [5% acetonitrile (AcN) (CH_3CN) and 0.1% FA], and 2 μ l was injected onto the column. Liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) was performed either on a Q-Exactive Plus Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher Scientific) equipped with an Easy nLC 1000 liquid chromatography system (Thermo Fisher Scientific) or an Orbitrap Fusion Lumos Tribrid Mass Spectrometer (Thermo Fisher Scientific) equipped with an Easy nLC 1200 liquid chromatography system (Thermo Fisher Scientific). Peptides were trapped on an Acclaim PepMap 100, 3- μ m C18, 75 μ m by 20 mm nano-trap column (Thermo Fisher Scientific) and separated on a 75 μ m by 250 mm (Q-Exactive) or 500 mm (Orbitrap Fusion Lumos), 2- μ m C18, 100 \AA EASY-Spray column (Thermo Fisher Scientific). The analytical separation used a gradient of $\text{H}_2\text{O}/0.1\%$ FA (solvent A) and $\text{CH}_3\text{CN}/0.1\%$ FA (solvent B). The gradient was run as follows: 95% A and 5% B for 0 to 5 min, then to 65% A and 35% B for 60 min, then to 10% A and 90% B for 10 min, and lastly to 10% A and 90% B for 15 min. Flow rate was 250 nl/min for a total run time of 90 min.

Data-dependent analysis (DDA) was performed on the Q-Exactive Plus with MS1 full scan at a resolution of 70,000 full width at half maximum (FWHM) followed by MS2 scans on up to 15 selected precursors. MS1 was performed with an automatic gain control (AGC) target of 3×10^6 , a maximum injection time of 100 ms, and a scan range from 400 to 2000 m/z . MS2 was performed at a resolution of 17,500 FWHM with an AGC target at 1×10^5 and a maximum injection time of 50 ms. Isolation window was set at 1.6 m/z , and 27% normalized collision energy was used for higher-energy collisional dissociation (HCD). DDA was performed on the Orbitrap Fusion Lumos with MS1 full scan at a resolution of 120,000 FWHM followed by as many subsequent MS2 scans on selected precursors as possible within a 3-s maximum cycle time. MS1 was performed in the Orbitrap with an AGC target of 4×10^5 , a maximum injection time of 50 ms, and a scan range from 400 to 2000 m/z . MS2 was performed in the ion trap with a rapid scan rate, an AGC target of 1×10^4 , and a maximum injection time of 35 ms. Isolation window was set at 1.2 m/z , and 30% normalized collision energy was used for HCD.

Database searches

Peak lists (MGF file format) were generated from raw data using the MS Convert conversion tool from ProteoWizard. The peak list files were searched against the PlasmoDB *P.berghei* ANKA database (PlasmoDB.org, release 38, 5076 entries) combined with an in-house database of common contaminants using Mascot (Matrix Science, London, UK; version 2.5.1). Trypsin was selected as the enzyme, with one potential missed cleavage. Precursor ion tolerance was set to 10 parts per million (ppm) and fragment ion tolerance to 0.02 Da for Q-Exactive Plus data and to 0.6 for Lumos data. Variable amino acid modifications were oxidized methionine and deamination (asparagine and glutamine) as well as phosphorylated serine, threonine,

and tyrosine. Fixed amino acid modification was carbamidomethyl cysteine. The Mascot search was validated using Scaffold 4.8.4 (Proteome Software) with 1% of protein false discovery rate (FDR) and at least two unique peptides per protein with a 0.1% peptide FDR.

PCA analysis

Enrichment and PCA were performed in the statistical programming package “R” (www.r-project.org). Quantitative values were analyzed as log-transformed spectral count values and displayed in principal components with greatest degrees of variance.

Chemoproteomics

Kinobeads were prepared as described (62, 63). The chemoproteomic affinity capturing experiments were performed as previously described (62, 64). Briefly, Kinobeads were incubated with *P. falciparum* extract (65), which was preincubated with compound or DMSO (vehicle control). The experimental setup was such that 10 samples are measured in parallel [TMT 10-plex (66)] to generate values for the affinity of the beads to the bound proteins (“depletion” values, four samples) and to generate median inhibitory concentration values based on dose-dependent competition (six samples, 20 μ M, 1:3 dilutions) in a single experiment. Beads were transferred to Filter plates (Durapore polyvinylidene difluoride membrane, Merck Millipore), washed extensively, and eluted with SDS sample buffer (67).

Proteins were digested according to a modified single pot solid-phase sample preparation (SP3) protocol (68, 69). Proteins were digested by resuspending in 0.1 mM Hepes (pH 8.5) containing tris(2-carboxyethyl)phosphine (TCEP), chloracetamide, trypsin, and LysC following overnight incubation.

Peptides were labeled with isobaric mass tags (TMT10, Thermo Fisher Scientific, Waltham, MA) using the 10-plex TMT reagents, enabling relative quantification of 10 conditions in a single experiment (66, 70). Labeled peptide extracts were combined to a single sample per experiment, lyophilized, and subjected to LC-MS analysis.

Samples were injected into an UltiMate 3000 nanoRSLC (Dionex) coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific). Peptides were separated on reversed-phase columns (Reprosil) at 55°C by gradient elution (3.5 to 29% AcN in aqueous 0.1% FA, 3.5% DMSO) in 120 min. The instruments were operated with Tune 2.4 and Xcalibur 3.0 build 63.

Mascot 2.4 (Matrix Science, Boston, MA) was used for protein identification by using a 10 parts per million mass tolerance for peptide precursors and 20 mD (HCD) mass tolerance for fragment ions. To create the FASTA file for mascot searching, all proteins corresponding to the taxonomy “*Plasmodium falciparum* (isolate 3D7)” were downloaded from UniProt (release 20170621) and supplemented with common contaminant protein sequences of BSA, porcine trypsin, and mouse, rat, sheep, and dog keratins. To assess the FDR, “decoy” proteins (reverse of all protein sequences) were created and added to the database, resulting in a database containing a total of 14,266 protein sequences, 50% forward and 50% reverse.

Unless stated otherwise, we accepted protein identifications as follows: (i) For single-spectrum to sequence assignments, we required this assignment to be the best match and a minimum Mascot score of 31 and a 10 \times difference of this assignment over the next best assignment. On the basis of these criteria, the decoy search results indicated <1% FDR. (ii) For multiple spectrum to sequence assignments and using the same parameters, the decoy search results indicated <0.1% FDR. Quantified proteins were required to contain

at least two unique peptide matches. FDR for quantified proteins was <0.1%.

P. falciparum phosphoproteomics

Parasite pellets were treated as previously described (71). Briefly, schizont pellets were resuspended in 1 ml of 8 M urea in 50 mM Hepes (pH 8.5), containing protease and phosphatase inhibitors and benzamide (100 U/ml; Sigma-Aldrich). Proteins were extracted from the pellets by sonication. Samples were incubated on ice for 10 min and centrifuged for 30 min at 14,000 rpm at 4°C. Protein content was estimated by a BCA protein assay, and 200 μ g of each sample was reduced with 10 mM DTT for 25 min at 56°C and then alkylated with 20 mM iodoacetamide for 30 min at room temperature. Samples were digested initially with LysC (Wako) at 37°C for 2.5 hours and subsequently with 10 μ g of trypsin (modified sequencing grade, Promega) overnight. After acidification, C₁₈ MacroSpin columns (Nest Group) were used to clean up the digested peptide solutions and the eluted peptides dried by vacuum centrifugation. Samples were resuspended in 50 mM Hepes and labeled using the 0.8 mg Tandem Mass Tag 10plex isobaric reagent kit (Thermo Fisher Scientific) following the manufacturer’s instructions. The eluted TMT-labeled peptides were dried by vacuum centrifugation, and phosphopeptide enrichment was subsequently carried out using the sequential metal oxide affinity chromatography strategy with High Select TiO₂ and Fe-NTA enrichment kits (Thermo Fisher Scientific). Eluates were combined before fractionation with the Pierce High pH Reversed-Phase Peptide Fractionation kit (Thermo Fisher Scientific). The dried TMT-labeled phosphopeptide fractions generated were resuspended in 0.1% TFA for LC-MS/MS analysis using a UltiMate 3000 RSLCnano system (Thermo Fisher Scientific) interfaced with an Orbitrap Fusion Lumos (Thermo Fisher Scientific). Each peptide fraction was pre-concentrated on an Acclaim PepMap 100 trapping column before separation on a 50-cm, 75- μ m I.D. EASY-Spray PepMap column over a 3-hour gradient run at 40°C, eluted directly into the mass spectrometer. The instrument was run in data-dependent acquisition mode with the most abundant peptides selected for MS/MS fragmentation. Two replicate injections were made for each fraction with different fragmentation methods based on the MS² HCD and MSA SPS MS³ strategies described (72). The acquired raw mass spectrometric data were processed in MaxQuant (73) (v1.6.2.10) and searched against UniProt *Homo sapiens* complete proteome canonical sequences (September 2019) and PlasmoDB. Fixed modifications were set as Carbamidomethyl (C) and variable modifications set as Oxidation (M) and Phospho (STY). The estimated FDR was set to 1% at the peptide, protein, and site levels. A maximum of two missed cleavages were allowed. Reporter ion MS² or Reporter ion MS³ was appropriately selected for each raw file. Other parameters were used as preset in the software. The MaxQuant output file PhosphoSTY Sites.txt, an FDR-controlled site-based table compiled by MaxQuant from the relevant information about the identified peptides, was imported into Perseus (v1.4.0.2) for data evaluation. Sequence logos were generated by IceLogo (<https://iomics.ugent.be/icelogo/server/>). Paired *t* tests were performed using R (R Core Team, 2017; www.R-project.org/). Significantly down-regulated genes from PfPKG and PfICM1 phosphoproteomes were used for enrichment of GO terms in PlasmoDB using a cutoff *P* value of 0.05. Results were visualized using REVIGO (74) with the *P. falciparum* database and similarity: 0.7, semantic similarity measure: SimRel. Plots were made using R (R Core Team, 2017; www.R-project.org/) package ggplot2 (75).

P. berghei* phosphoproteomics*Sample preparation**

Samples (about 100 μ l of packed cell volume) were diluted with 25 μ l of Laemmli 5 \times buffer and sonicated 6 \times 30 s at 70% amplitude and 0.5 pulse (30 s on ice between each cycle). Samples were heated 5 min at 65°C and loaded onto a Novex Wedgewell 12% tris-glycine gel (Invitrogen). Each sample was loaded on two different wells, and protein's migration was then performed according to the manufacturer's instructions. Proteins were then stained with Coomassie blue. For each lane, a band between 180 and 220 kDa was cut and destained by incubation in 100 μ l of 30% AcN in 50 mM AB for 15 min at room temperature. Proteins were reduced by incubation of gel pieces for 35 min at 56°C in 100 μ l of 10 mM DTE in 50 mM AB. DTE solution was then replaced by 100 μ l of 55 mM iodoacetamide in 50 mM AB, and proteins were alkylated by incubation of the gel pieces for 30 min at room temperature in the dark. Gel pieces were then washed for 10 min with 100 μ l of 50 mM AB and dehydrated for 10 min with 100 μ l of 30% AcN. Gel pieces were then dried for 30 min in a vacuum centrifuge. Dried pieces of gel were rehydrated for 45 min at 4°C with 70 μ l of trypsin (6.25 ng/ μ l in AB 50 mM) and then incubated overnight at 37°C. The supernatant was transferred to a new polypropylene tube, and two additional peptide extraction were performed with 70 μ l of 1% TFA and 100 μ l of 50% ACN, respectively; 0.1% TFA. Extractions were pooled and dried under speed vacuum.

Titanium dioxide enrichment

Phosphopeptide enrichment was performed as previously described (76). Briefly, stage tips were prepared using Glass Microfiber Filters (Whatman) and 5- μ m TiO₂ beads (GL Sciences). Beads were suspended with 0.1% TFA in 80% AcN and inserted onto a gel-loading tip to create a 5-mm-long column. Peptides samples were dissolved in 1 M glycolic acid 2% TFA in 80% AcN and loaded onto dedicated TiO₂ columns by centrifugation 1 min at 6000 rpm. Columns were then washed four times with 1 M glycolic acid 2% TFA in 80% AcN and four times with 0.1% TFA in 80% AcN. Bounded peptides were eluted first with 3% NH₄OH and then with 0.1% TFA in 80% AcN. Eluates were then acidified with 5% TFA and dried under speed vacuum.

Fe-NTA enrichment

Flow through from TiO₂ beads were enriched using homemade stage tips as described before but containing beads from the High-Select Fe-NTA Phosphopeptide Enrichment Kit (Thermo Fisher Scientific). Enrichment was performed according to the manufacturer's instructions.

Liquid chromatography electrospray ionization tandem mass spectrometry

Samples were diluted in 10 μ l of loading buffer (5% CH₃CN and 0.1% FA), and 6 μ l was injected on column. LC-ESI-MS/MS was performed on an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific) equipped with an Easy nLC1200 liquid chromatography system (Thermo Fisher Scientific). Peptides were trapped on an Acclaim PepMap 100, 3- μ m C18, 75 μ m by 20 mm nano-trap column (Thermo Fisher Scientific) and separated on a 75 μ m by 500 mm, C18 ReproSil-Pur from Dr. Maisch GmbH, 1.9 μ m and 100 Å, homemade column. The analytical separation was run for 90 min using a gradient of H₂O/FA 99.9%/0.1% (solvent A) and CH₃CN/FA 80%/0.1% (solvent B). The gradient was run as follows: 95% A and 5% B for 0 to 5 min, then to 65% A and 35% B for 60 min, and lastly to 5% A and 95% B for 10 min with a stay for 15 min at this composition. Flow rate was of 250 nl/min. DDA was performed

with MS1 full scan at a resolution of 120,000 FWHM followed by as many subsequent MS2 scans on selected precursors as possible within 3-s maximum cycle time. MS1 was performed in the Orbitrap with an AGC target of 4×10^5 , a maximum injection time of 50 ms, and a scan range from 375 to 1500 *m/z*. MS2 was performed in the Orbitrap at a resolution of 30,000 FWHM with an AGC target at 5×10^4 and a maximum injection time of 54 ms. Isolation windows was set at 1.6 *m/z*, and 30% normalized collision energy was used for HCD.

Database search

Raw data were processed using Proteome Discoverer 2.3 software (Thermo Fisher Scientific). Briefly, spectra were extracted and searched against the *P. berghei* ANKA database (PlasmoDB.org, release 38, 5076 entries) combined with an in-house database of common contaminants using Mascot (Matrix Science, London, UK; version 2.5.1). Trypsin was selected as the enzyme, with one potential missed cleavage. Precursor ion tolerance was set to 10 ppm and fragment ion tolerance to 0.02 Da. Carbamidomethylation of cysteine was specified as fixed modification. Deamidation of asparagine and glutamine, oxidation of methionine, as well as phosphorylation of serine, threonine, and tyrosine were specified as variable modifications. Peptide-spectrum matches were validated using the target decoy PSM validator node with a target FDR of 0.01 and a Delta Cn of 0.5. For label-free quantification, features and chromatographic peaks were detected using the "Minora Feature Detector" node with the default parameters. PSM and peptides were filtered with a FDR of 1% and then grouped to proteins with again an FDR of 1% and using only peptides with a high confidence level. Both unique and razor peptides were used for quantitation, and protein abundances are calculated as the average of the three most abundant distinct peptide groups. The abundances were normalized on the "total peptide amount," then "protein abundance-based" option was selected for protein ratio calculation, and associated *P* values were calculated with an analysis of variance (ANOVA) test (individual proteins).

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <http://advances.sciencemag.org/cgi/content/full/7/13/eabe5396/DC1>

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

1. WHO, World malaria report (2019).
2. D. A. Baker, L. G. Drought, C. Flueck, S. D. Nofal, A. Patel, M. Penzo, E. M. Walker, Cyclic nucleotide signalling in malaria parasites. *Open Biol.* **7**, 170213 (2017).
3. M. Brochet, O. Billker, Calcium signalling in malaria parasites. *Mol. Microbiol.* **100**, 397–408 (2016).
4. H. M. Taylor, L. McRobert, M. Grainger, A. Sicard, A. R. Dlugowski, C. S. Hopp, A. A. Holder, D. A. Baker, The malaria parasite cyclic GMP-dependent protein kinase plays a central role in blood-stage schizogony. *Eukaryot. Cell* **9**, 37–45 (2010).
5. K. Koussis, C. Withers-Martinez, D. A. Baker, M. J. Blackman, Simultaneous multiple allelic replacement in the malaria parasite enables dissection of PKG function. *Life Sci. Alliance* **3**, e201900626 (2020).
6. A. Falae, A. Combe, A. Amaladoss, T. Carvalho, R. Menard, P. Bhanot, Role of Plasmodium berghei cGMP-dependent protein kinase in late liver stage development. *J. Biol. Chem.* **285**, 3282–3288 (2010).
7. L. McRobert, C. J. Taylor, W. Deng, Q. L. Fivelman, R. M. Cummings, S. D. Polley, O. Billker, D. A. Baker, Gametogenesis in malaria parasites is mediated by the cGMP-dependent protein kinase. *PLoS Biol.* **6**, e139 (2008).
8. M. Brochet, M. O. Collins, T. K. Smith, E. Thompson, S. Sebastian, K. Volkman, F. Schwach, L. Chappell, A. R. Gomes, M. Berriman, J. C. Rayner, D. A. Baker, J. Choudhary, O. Billker, Phosphoinositide metabolism links cGMP-dependent protein kinase G to essential Ca²⁺ signals at key decision points in the life cycle of malaria parasites. *PLoS Biol.* **12**, e1001806 (2014).

9. K. Govindasamy, S. Jebiwott, D. K. Jaijyan, A. Davidow, K. K. Ojo, W. C. van Voorhis, M. Brochet, O. Billker, P. Bhanot, Invasion of hepatocytes by *Plasmodium* sporozoites requires cGMP-dependent protein kinase and calcium dependent protein kinase 4. *Mol. Microbiol.* **102**, 349–363 (2016).
10. H. Fang, A. R. Gomes, N. Klages, P. Pino, B. Maco, E. M. Walker, Z. A. Zenonos, F. Angrisano, J. Baum, C. Doerig, D. A. Baker, O. Billker, M. Brochet, Epistasis studies reveal redundancy among calcium-dependent protein kinases in motility and invasion of malaria parasites. *Nat. Commun.* **9**, 4248 (2018).
11. S. H. Francis, J. L. Busch, J. D. Corbin, D. Sibley, cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. *Pharmacol. Rev.* **62**, 525–563 (2010).
12. L. Yang, G. Liu, S. I. Zakharov, A. M. Bellinger, M. Mongillo, S. O. Marx, Protein kinase G phosphorylates Cav1.2 alpha1c and beta2 subunits. *Circ. Res.* **101**, 465–474 (2007).
13. J. Schlossmann, A. Ammendola, K. Ashman, X. Zong, A. Huber, G. Neubauer, G. X. Wang, H. D. Allescher, M. Korth, M. Wilm, F. Hofmann, P. Ruth, Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta. *Nature* **404**, 197–201 (2000).
14. C. Xia, Z. Bao, C. Yue, B. M. Sanborn, M. Liu, Phosphorylation and regulation of G-protein-activated phospholipase C-β3 by cGMP-dependent protein kinases. *J. Biol. Chem.* **276**, 19770–19777 (2001).
15. A. Koller, J. Schlossmann, K. Ashman, S. Uttenweiler-Joseph, P. Ruth, F. Hofmann, Association of phospholamban with a cGMP kinase signaling complex. *Biochem. Biophys. Res. Commun.* **300**, 155–160 (2003).
16. S. L. Baldauf, The deep roots of eukaryotes. *Science* **300**, 1703–1706 (2003).
17. C. S. Hopp, C. Flueck, L. Solyakov, A. Tobin, D. A. Baker, Spatiotemporal and functional characterisation of the *Plasmodium falciparum* cGMP-dependent protein kinase. *PLoS ONE* **7**, e48206 (2012).
18. D. A. Baker, L. B. Stewart, J. M. Large, P. W. Bowyer, K. H. Ansell, M. B. Jiménez-Díaz, M. el Bakkouri, K. Birchall, K. J. Dechering, N. S. Boulou, P. J. Coombs, D. Whalley, D. J. Harding, E. Smiljanic-Hurley, M. C. Wheldon, E. M. Walker, J. T. Dessens, M. J. Lafuente, L. M. Sanz, F. J. Gamó, S. B. Ferrer, R. Hui, T. Bousema, I. Angulo-Barturén, A. T. Merritt, S. L. Croft, W. E. Gutteridge, C. A. Kettleborough, S. A. Osborne, A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission. *Nat. Commun.* **8**, 430 (2017).
19. M. Bantscheff, D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, S. Hobson, T. Mathieson, J. Perrin, M. Raida, C. Rau, V. Reader, G. Sweetman, A. Bauer, T. Bouwmeester, C. Hopf, U. Kruse, G. Neubauer, N. Ramsden, J. Rick, B. Kuster, G. Drewes, Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. *Nat. Biotechnol.* **25**, 1035–1044 (2007).
20. R. Tewari, U. Straschil, A. Bateman, U. Böhme, I. Cherevach, P. Gong, A. Pain, O. Billker, The systematic functional analysis of *Plasmodium* protein kinases identifies essential regulators of mosquito transmission. *Cell Host Microbe* **8**, 377–387 (2010).
21. A. C. Balestra, M. Zeeshan, E. Rea, C. Pasquarello, L. Brusini, T. Mourier, A. K. Subudhi, N. Klages, P. Arboit, R. Pandey, D. Brady, S. Vaughan, A. A. Holder, A. Pain, D. J. P. Ferguson, A. Hainard, R. Tewari, M. Brochet, A divergent cyclin/cyclin-dependent kinase complex controls the atypical replication of a malaria parasite during gametogony and transmission. *eLife* **9**, e56474 (2020).
22. L. A. Kelley, S. Mezulis, C. M. Yates, M. N. Wass, M. J. Sternberg, The Phyre2 web portal for protein modeling, prediction and analysis. *Nat. Protoc.* **10**, 845–858 (2015).
23. L. Solyakov, J. Halbert, M. M. Alam, J. P. Semblat, D. Dorin-Semblat, L. Reiningger, A. R. Bottrill, S. Mistry, A. Abdi, C. Fennell, Z. Holland, C. Demarta, Y. Bouza, A. Sicard, M. P. Nivez, S. Eschenlauer, T. Lama, D. C. Thomas, P. Sharma, S. Agarwal, S. Kern, G. Pradel, M. Graciotti, A. B. Tobin, C. Doerig, Global kinomic and phospho-proteomic analyses of the human malaria parasite *Plasmodium falciparum*. *Nat. Commun.* **2**, 565 (2011).
24. M. Trecek, J. L. Sanders, J. E. Elias, J. C. Boothroyd, The Phosphoproteomes of *Plasmodium falciparum* and *Toxoplasma gondii* Reveal Unusual Adaptations Within and Beyond the Parasites' Boundaries. *Cell Host Microbe* **10**, 410–419 (2011).
25. M. M. Alam, L. Solyakov, A. R. Bottrill, C. Flueck, F. A. Siddiqui, S. Singh, S. Mistry, M. Viskaduraki, K. Lee, C. S. Hopp, C. E. Chitnis, C. Doerig, R. W. Moon, J. L. Green, A. A. Holder, D. A. Baker, A. B. Tobin, Phosphoproteomics reveals malaria parasite Protein Kinase G as a signalling hub regulating egress and invasion. *Nat. Commun.* **6**, 7285 (2015).
26. B. M. Invergo, M. Brochet, L. Yu, J. Choudhary, P. Beltrao, O. Billker, Sub-minute phosphoregulation of cell cycle systems during *Plasmodium* gamete formation. *Cell Rep.* **21**, 2017–2029 (2017).
27. R. W. Moon, C. J. Taylor, C. Bex, R. Schepers, D. Goulding, C. J. Janse, A. P. Waters, D. A. Baker, O. Billker, A cyclic GMP signalling module that regulates gliding motility in a malaria parasite. *PLoS Pathog.* **5**, e1000599 (2009).
28. J. L. Green, R. W. Moon, D. Whalley, P. W. Bowyer, C. Wallace, A. Rochani, R. K. Nageshan, S. A. Howell, M. Grainger, H. M. Jones, K. H. Ansell, T. M. Chapman, D. L. Taylor, S. A. Osborne, D. A. Baker, U. Tatu, A. A. Holder, Imidazopyridazine inhibitors of *Plasmodium falciparum* calcium-dependent protein kinase 1 also target cyclic GMP-dependent protein kinase and heat shock protein 90 to kill the parasite at different stages of intracellular development. *Antimicrob. Agents Chemother.* **60**, 1464–1475 (2015).
29. O. Billker, S. Dechamps, R. Tewari, G. Wenig, B. Franke-Fayard, V. Brinkmann, Calcium and a calcium-dependent protein kinase regulate gamete formation and mosquito transmission in a malaria parasite. *Cell* **117**, 503–514 (2004).
30. H. Fang, N. Klages, B. Baechler, E. Hillner, L. Yu, M. Pardo, J. Choudhary, M. Brochet, Multiple short windows of calcium-dependent protein kinase 4 activity coordinate distinct cell cycle events during *Plasmodium* gametogenesis. *eLife* **6**, e26524 (2017).
31. E. Bushell, A. R. Gomes, T. Sanderson, B. Anar, G. Girling, C. Herd, T. Metcalf, K. Modrzynska, F. Schwach, R. E. Martin, M. W. Mather, G. I. McFadden, L. Parts, G. G. Rutledge, A. B. Vaidya, K. Wengelnik, J. C. Rayner, O. Billker, Functional profiling of a *Plasmodium* genome reveals an abundance of essential genes. *Cell* **170**, 260–272.e8 (2017).
32. C. P. Sayers, V. Mollard, H. D. Buchanan, G. I. McFadden, C. D. Goodman, A genetic screen in rodent malaria parasites identifies five new apicomplast putative membrane transporters, one of which is essential in human malaria parasites. *Cell. Microbiol.* **20**, (2018).
33. C. Pfander, B. Anar, M. Brochet, J. C. Rayner, O. Billker, Recombination-mediated genetic engineering of *Plasmodium berghei* DNA. *Methods Mol. Biol.* **923**, 127–138 (2013).
34. C. Pfander, B. Anar, F. Schwach, T. D. Otto, M. Brochet, K. Volkmann, M. A. Quail, A. Pain, B. Rosen, W. Skarnes, J. C. Rayner, O. Billker, A scalable pipeline for highly effective genetic modification of a malaria parasite. *Nat. Methods* **8**, 1078–1082 (2011).
35. N. Philip, A. P. Waters, Conditional degradation of *Plasmodium* calcineurin reveals functions in parasite colonization of both host and vector. *Cell Host Microbe* **18**, 122–131 (2015).
36. S. Sebastian, M. Brochet, M. O. Collins, F. Schwach, M. L. Jones, D. Goulding, J. C. Rayner, J. S. Choudhary, O. Billker, A *Plasmodium* calcium-dependent protein kinase controls zygote development and transmission by translationally activating repressed mRNAs. *Cell Host Microbe* **12**, 9–19 (2012).
37. B. L. Howard, K. L. Harvey, R. J. Stewart, M. F. Azevedo, B. S. Crabb, I. G. Jennings, P. R. Sanders, D. T. Manallack, P. E. Thompson, C. J. Tonkin, P. R. Gilson, Identification of potent phosphodiesterase inhibitors that demonstrate cyclic nucleotide-dependent functions in apicomplexan parasites. *ACS Chem. Biol.* **10**, 1145–1154 (2015).
38. M. Zhang, C. Wang, T. D. Otto, J. Oberstaller, X. Liao, S. R. Adapa, K. Udenze, I. F. Bronner, D. Casandra, M. Mayho, J. Brown, S. Li, J. Swanson, J. C. Rayner, R. H. Y. Jiang, J. H. Adams, Uncovering the essential genes of the human malaria parasite *Plasmodium falciparum* by saturation mutagenesis. *Science* **360**, eaap7847 (2018).
39. A. J. Perrin, C. R. Collins, M. R. G. Russell, L. M. Collinson, D. A. Baker, M. J. Blackman, The actinomyosin motor drives malaria parasite red blood cell invasion but not egress. *MBio* **9**, e00905-18 (2018).
40. J. A. Thomas, M. S. Y. Tan, C. Bisson, A. Borg, T. R. Umrekar, F. Hackett, V. L. Hale, G. Vizcay-Barrena, R. A. Fleck, A. P. Snijders, H. R. Saibil, M. J. Blackman, A protease cascade regulates release of the human malaria parasite *Plasmodium falciparum* from host red blood cells. *Nat. Microbiol.* **3**, 447–455 (2018).
41. C. R. Collins, F. Hackett, M. Strath, M. Penzo, C. Withers-Martinez, D. A. Baker, M. J. Blackman, Malaria parasite cGMP-dependent protein kinase regulates blood stage merozoite secretory organelle discharge and egress. *PLoS Pathog.* **9**, e1003344 (2013).
42. J. Healer, S. Crawford, S. Ralph, G. McFadden, A. F. Cowman, Independent translocation of two micronemal proteins in developing *Plasmodium falciparum* merozoites. *Infect. Immun.* **70**, 5751–5758 (2002).
43. S. Absalon, K. Blomqvist, R. M. Rudlaff, T. J. De Lano, M. P. Pollastri, J. D. Dvorin, Calcium-dependent protein kinase 5 is required for release of egress-specific organelles in *Plasmodium falciparum*. *MBio* **9**, e00130-18 (2018).
44. K. Blomqvist, M. Helmelt, C. Wang, S. Absalon, T. Labunska, R. M. Rudlaff, S. Adapa, R. Jiang, H. Steen, J. D. Dvorin, Influence of *Plasmodium falciparum* calcium-dependent protein kinase 5 (PfCDPK5) on the late schizont stage phosphoproteome. *mSphere* **5**, e00921-19 (2020).
45. J. J. Carlisle Michel, K. L. Dodge, W. Wong, N. C. Mayer, L. K. Langeberg, J. D. Scott, PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. *Biochem. J.* **381**, 587–592 (2004).
46. M. Meister, A. Tomasovic, A. Banning, R. Tikkanen, Mitogen-activated protein (MAP) kinase scaffolding proteins: A recount. *Int. J. Mol. Sci.* **14**, 4854–4884 (2013).

47. K. Yuasa, K. Omori, N. Yanaka, Binding and phosphorylation of a novel male germ cell-specific cGMP-dependent protein kinase-anchoring protein by cGMP-dependent protein kinase Ia. *J. Biol. Chem.* **275**, 4897–4905 (2000).
48. D. E. Casteel, S. Zhuang, T. Gudi, J. Tang, M. Vuica, S. Desiderio, R. B. Pilz, cGMP-dependent protein kinase Iβ physically and functionally interacts with the transcriptional regulator TFII-I. *J. Biol. Chem.* **277**, 32003–32014 (2002).
49. H. K. Surks, N. Mochizuki, Y. Kasai, S. P. Georgescu, K. M. Tang, M. Ito, T. M. Lincoln, M. E. Mendelsohn, Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase alpha. *Science* **286**, 1583–1587 (1999).
50. K. Govindasamy, R. Khan, M. Snyder, H. J. Lou, P. Du, H. M. Kudyba, V. Muralidharan, B. E. Turk, P. Bhanot, *Plasmodium falciparum* cyclic GMP-dependent protein kinase interacts with a subunit of the parasite proteasome. *Infect. Immun.* **87**, e00523-18 (2019).
51. M. Vanaerschot, J. M. Murithi, C. F. A. Pasaje, S. Ghidelli-Disse, L. Dwomoh, M. Bird, N. Spottiswoode, N. Mittal, L. B. Arendse, E. S. Owen, K. J. Wicht, G. Siciliano, M. Bösch, T. Yeo, T. R. S. Kumar, S. Mok, E. F. Carpenter, M. J. Giddins, O. Sanz, S. Otilie, P. Alano, K. Chibale, M. Llinás, A.-C. Uhlemann, M. Delves, A. B. Tobin, C. Doerig, E. A. Szlezler, M. C. S. Lee, J. C. Niles, D. A. Fidock, Inhibition of resistance-refractory *P. falciparum* kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. *Cell Chem. Biol.* **27**, 806–816.e8 (2020).
52. S. M. Ganesan, A. Falla, S. J. Goldfless, A. S. Nasamu, J. C. Niles, Synthetic RNA-protein modules integrated with native translation mechanisms to control gene expression in malaria parasites. *Nat. Commun.* **7**, 10727 (2016).
53. S. Das, N. Hertrich, A. J. Perrin, C. Withers-Martinez, C. R. Collins, M. L. Jones, J. M. Watermeyer, E. T. Fobes, S. R. Martin, H. R. Saibil, G. J. Wright, M. Treeck, C. Epp, M. J. Blackman, Processing of *Plasmodium falciparum* merozoite surface protein MSP1 activates a spectrin-binding function enabling parasite egress from RBCs. *Cell Host Microbe* **18**, 433–444 (2015).
54. C. R. Collins, S. Das, E. H. Wong, N. Andenmatten, R. Stallmach, F. Hackett, J. P. Herman, S. Müller, M. Meissner, M. J. Blackman, Robust inducible Cre recombinase activity in the human malaria parasite *Plasmodium falciparum* enables efficient gene deletion within a single asexual erythrocytic growth cycle. *Mol. Microbiol.* **88**, 687–701 (2013).
55. T. W. Kooij, M. M. Rauch, K. Matuschewski, Expansion of experimental genetics approaches for *Plasmodium berghei* with versatile transfection vectors. *Mol. Biochem. Parasitol.* **185**, 19–26 (2012).
56. E. Knuepfer, M. Napiorkowska, C. van Ooij, A. A. Holder, Generating conditional gene knockouts in *Plasmodium* – a toolkit to produce stable DiCre recombinase-expressing parasite lines using CRISPR/Cas9. *Sci. Rep.* **7**, 3881–3881 (2017).
57. J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J. Y. Tinevez, D. J. White, V. Hartenstein, K. Eliceiri, P. Tomancak, A. Cardona, Fiji: An open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
58. K. Volkmann, C. Pfander, C. Burstroem, M. Ahras, D. Goulding, J. C. Rayner, F. Frischknecht, O. Billker, M. Brochet, The alveolin IMC1h is required for normal ookinete and sporozoite motility behaviour and host colonisation in *Plasmodium berghei*. *PLOS ONE* **7**, e41409 (2012).
59. J. Yang, R. Yan, A. Roy, D. Xu, J. Poisson, Y. Zhang, The I-TASSER Suite: Protein structure and function prediction. *Nat. Methods* **12**, 7–8 (2015).
60. A. Roy, A. Kucukural, Y. Zhang, I-TASSER: A unified platform for automated protein structure and function prediction. *Nat. Protoc.* **5**, 725–738 (2010).
61. Y. Zhang, I-TASSER server for protein 3D structure prediction. *BMC Bioinformatics* **9**, 40 (2008).
62. M. Bantscheff, C. Hopf, M. M. Savitski, A. Dittmann, P. Grandi, A. M. Michon, J. Schlegl, Y. Abraham, I. Becher, G. Bergamini, M. Boesche, M. Dellling, B. Dümpelfeld, D. Eberhard, C. Huthmacher, T. Mathieson, D. PoECKel, V. Reader, K. Strunk, G. Sweetman, U. Kruse, G. Neubauer, N. G. Ramsden, G. Drewes, Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. *Nat. Biotechnol.* **29**, 255–265 (2011).
63. G. Bergamini, K. Bell, S. Shimamura, T. Werner, A. Cansfield, K. Müller, J. Perrin, C. Rau, K. Ellard, C. Hopf, C. Doce, D. Leggate, R. Mangano, T. Mathieson, A. O'Mahony, I. Plavec, F. Rharbaoui, F. Reinhard, M. M. Savitski, N. Ramsden, E. Hirsch, G. Drewes, O. Rausch, M. Bantscheff, G. Neubauer, A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation. *Nat. Chem. Biol.* **8**, 576–582 (2012).
64. A. N. Matralis, A. Malik, M. Penzo, I. Moreno, M. J. Almela, I. Camino, B. Crespo, A. Saadeddin, S. Ghidelli-Disse, L. Rueda, F. Calderon, S. A. Osborne, G. Drewes, M. Bösch, E. Fernández-Álvarez, J. I. Martín Hernández, D. A. Baker, Development of chemical entities endowed with potent fast-killing properties against *Plasmodium falciparum* malaria parasites. *J. Med. Chem.* **62**, 9217–9235 (2019).
65. T. Paquet, C. le Manach, D. G. Cabrera, Y. Younis, P. P. Henrich, T. S. Abraham, M. C. S. Lee, R. Basak, S. Ghidelli-Disse, M. J. Lafuente-Monasterio, M. Bantscheff, A. Ruecker, A. M. Blagborough, S. E. Zakutansky, A. M. Zeeman, K. L. White, D. M. Shackleford, J. Mannila, J. Morizzi, C. Scheurer, I. Angulo-Barturen, M. S. Martínez, S. Ferrer, L. M. Sanz, F. J. Gamo, J. Reader, M. Botha, K. J. Dechering, R. W. Sauerwein, A. Tungtaeng, P. Vanachayangkul, C. S. Lim, J. Burrows, M. J. Wittey, K. C. Marsh, C. Bodenreider, R. Rochford, S. M. Solapure, M. B. Jiménez-Díaz, S. Wittlin, S. A. Charman, C. Donini, B. Campo, L. M. Birkholtz, K. K. Hanson, G. Drewes, C. H. M. Kocken, M. J. Delves, D. Leroy, D. A. Fidock, D. Waterson, L. J. Street, K. Chibale, Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. *Sci. Transl. Med.* **9**, eaa9735 (2017).
66. T. Werner, G. Sweetman, M. F. Savitski, T. Mathieson, M. Bantscheff, M. M. Savitski, Ion coalescence of neutron encoded TMT 10-plex reporter ions. *Anal. Chem.* **86**, 3594–3601 (2014).
67. H. C. Eberl, T. Werner, F. B. Reinhard, S. Lehmann, D. Thomson, P. Chen, C. Zhang, C. Rau, M. Muelbauer, G. Drewes, D. Drewry, M. Bantscheff, Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells. *Sci. Rep.* **9**, 14159 (2019).
68. C. S. Hughes, S. Foehr, D. A. Garfield, E. E. Furlong, L. M. Steinmetz, J. Krijgsveld, Ultrasensitive proteome analysis using paramagnetic bead technology. *Mol. Syst. Biol.* **10**, 757 (2014).
69. S. Moggridge, P. H. Sorensen, G. B. Morin, C. S. Hughes, Extending the compatibility of the SP3 paramagnetic bead processing approach for proteomics. *J. Proteome Res.* **17**, 1730–1740 (2018).
70. T. Werner, I. Becher, G. Sweetman, C. Doce, M. M. Savitski, M. Bantscheff, High-resolution enabled TMT 8-plexing. *Anal. Chem.* **84**, 7188–7194 (2012).
71. A. Patel, A. J. Perrin, H. R. Flynn, C. Bisson, C. Withers-Martinez, M. Treeck, C. Flueck, G. Nicastro, S. R. Martin, A. Ramos, T. W. Gilberger, P. A. Snijders, M. J. Blackman, D. A. Baker, Cyclic AMP signalling controls key components of malaria parasite host cell invasion machinery. *PLoS Biol.* **17**, e3000264 (2019).
72. X. Jiang, R. Bomgardner, J. Brown, D. L. Drew, A. M. Robitaille, R. Viner, A. R. Huhmer, Sensitive and accurate quantitation of phosphopeptides using TMT isobaric labeling technique. *J. Proteome Res.* **16**, 4244–4252 (2017).
73. J. Cox, M. Mann, MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **26**, 1367–1372 (2008).
74. F. Supek, M. Bošnjak, N. Škunca, T. Šmuc, REVIGO summarizes and visualizes long lists of gene ontology terms. *PLOS ONE* **6**, e21800 (2011).
75. H. Wickham, in *ggplot2: Elegant Graphics for Data Analysis* (Springer International Publishing, 2016), pp. 11–31.
76. S. S. Jensen, M. R. Larsen, Evaluation of the impact of some experimental procedures on different phosphopeptide enrichment techniques. *Rapid Commun. Mass Spectrom.* **21**, 3635–3645 (2007).
77. Y. Perez-Riverol, A. Csordas, J. Bai, M. Bernal-Llinares, S. Hewapathirana, D. J. Kundu, A. Inuganti, J. Griss, G. Mayer, M. Eisenacher, E. Pérez, J. Uszkoreit, J. Pfeuffer, T. Sachsenberg, Ş. Yilmaz, S. Tiwary, J. Cox, E. Audain, M. Walzer, A. F. Jarnuczak, T. Tertent, A. Brazma, J. A. Vizcaino, The PRIDE database and related tools and resources in 2019: Improving support for quantification data. *Nucleic Acids Res.* **47**, D442–D450 (2019).

Acknowledgments: We thank the excellent service at the bioimaging and flow cytometry core facilities at the Faculty of Medicine of the University of Geneva. M.B. is grateful to O. Billker for support during the initial steps of this project. We would also like to acknowledge E. Fernández-Álvarez at GSK for support in the initial stages of the project and S. Osborne at LifeArc who was the lead chemist on the project that generated ML10.

Funding: This work was supported by the Swiss National Science Foundation (starting grant BSSGI0_155852), by the Novartis Foundation (19C189), and by the Fondation privée des Hôpitaux Universitaires de Genève (CONFIRM grant RC05-10) to M.B. M.B. is an INSERM and EMBO young investigator. This work was also supported by Wellcome Trust grant 106239/Z/14/A (to K.K., A.J.P., and M.J.B.), Wellcome Trust grant 106240/Z/14/Z (to D.A.B.), MRC Developmental pathway funding scheme grant (ref G10000779) (to D.A.B.), and Wellcome ISSF2 funding to the London School of Hygiene & Tropical Medicine. The work was also supported by funding to M.J.B. from the Francis Crick Institute (www.crick.ac.uk/), which receives its core funding from Cancer Research UK (FC001043; www.cancerresearchuk.org), the UK Medical Research Council (FC001043; www.mrc.ac.uk/), and the Wellcome Trust (FC001043; https://wellcome.ac.uk/). This research was funded, in part, by the Wellcome Trust. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any author accepted manuscript version arising from this submission. **Author contributions:** Conceptualization: K.K., D.A.B., M.J.B., and M.B. Methodology, formal analysis, and investigation: A.C.B., K.K., N.K., S.A.H., H.R.F., M.B., C.P., A.J.P., L.B., P.A., O.S., L.P.-B.C., C.W.-M., and A.H. Writing—original draft: A.C.B., K.K., D.A.B., M.J.B., and M.B. Writing—review

and editing: A.C.B., K.K., S.A.H., H.R.F., A.J.P., C.W.-M., S.G.-D., D.A.B., M.J.B., and M.B. Funding acquisition: D.A.B., M.J.B., and M.B. Resources: S.G.-D., A.P.S., D.A.B., M.J.B., and M.B. Supervision: S.G.-D., A.P.S., D.A.B., M.J.B., and M.B. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (77) partner repository (<http://proteomecentral.proteomexchange.org>) with the dataset identifiers PXD020210 (*P. berghei* IP), PXD020189 (*P. berghei* proteomics), PXD020447 (*P. falciparum* IP), and PXD020381 (*P. falciparum* proteomics). Additional data related to this paper may be requested from the authors.

Submitted 28 August 2020

Accepted 5 February 2021

Published 24 March 2021

10.1126/sciadv.abe5396

Citation: A. C. Balestra, K. Koussis, N. Klages, S. A. Howell, H. R. Flynn, M. Bantscheff, C. Pasquarello, A. J. Perrin, L. Brusini, P. Arboit, O. Sanz, L. P.-B. Castaño, C. Withers-Martinez, A. Hainard, S. Ghidelli-Disse, A. P. Snijders, D. A. Baker, M. J. Blackman, M. Brochet, Ca²⁺ signals critical for egress and gametogenesis in malaria parasites depend on a multipass membrane protein that interacts with PKG. *Sci. Adv.* 7, eabe5396 (2021).

Ca²⁺ signals critical for egress and gametogenesis in malaria parasites depend on a multipass membrane protein that interacts with PKG

Aurélia C. Balestra, Konstantinos Koussis, Natacha Klages, Steven A. Howell, Helen R. Flynn, Marcus Bantscheff, Carla Pasquarello, Abigail J. Perrin, Lorenzo Brusini, Patrizia Arboit, Olalla Sanz, Laura Peces-Barba Castaño, Christlaine Withers-Martinez, Alexandre Hainard, Sonja Ghidelli-Disse, Ambrosius P. Snijders, David A. Baker, Michael J. Blackman and Mathieu Brochet

Sci Adv 7 (13), eabe5396.
DOI: 10.1126/sciadv.abe5396

ARTICLE TOOLS

<http://advances.sciencemag.org/content/7/13/eabe5396>

SUPPLEMENTARY MATERIALS

<http://advances.sciencemag.org/content/suppl/2021/03/22/7.13.eabe5396.DC1>

REFERENCES

This article cites 74 articles, 19 of which you can access for free
<http://advances.sciencemag.org/content/7/13/eabe5396#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

Science Advances (ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Advances* is a registered trademark of AAAS.

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).